Loading...

Kavanaugh, Arthur

TitleProfessor
InstitutionUniversity of California San Diego
DepartmentMedicine
Address9500 Gilman Drive #0943
La Jolla CA 92093
Phone858-657-7044
vCardDownload vCard

    Collapse Biography 
    Collapse Education and Training
    St. Louis University Medical School, St. Louis, MOMD
    Massachusetts Institute of Technology, Cambridge, MAABBiology

    Collapse Overview 
    Collapse Overview
    Research Interests
    Innovative strategies for the treatment of patients with rheumatoid arthritis and other rheumatic diseases. Prognostic and predictive factors for outcomes in rheumatic diseases. Research program on innovative approaches to various immunologic diseases, particularly novel biologic therapies.


    Collapse ORNG Applications 
    Collapse Clinical Trials
    Collapse Websites

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. Thomsen RS, Nilsen TIL, Haugeberg G, Bye A, Kavanaugh A, Hoff M. The impact of high intensity interval training on disease activity and patient disease perception in patients with psoriatic arthritis: A randomized controlled trial. Arthritis Care Res (Hoboken). 2018 Jun 08. PMID: 29882634.
      View in: PubMed
    2. Kavanaugh A, Singh R, Karki C, Etzel CJ, Kremer JM, Greenberg JD, Griffith J. Disease activity and biologic use in patients with psoriatic arthritis or rheumatoid arthritis. Clin Rheumatol. 2018 Jun 04. PMID: 29869112.
      View in: PubMed
    3. Strand V, Kavanaugh A, Kivitz AJ, van der Heijde D, Kwok K, Akylbekova E, Soonasra A, Snyder M, Connell C, Bananis E, Smolen JS. Long-Term Radiographic and Patient-Reported Outcomes in Patients with Rheumatoid Arthritis Treated with Tofacitinib: ORAL Start and ORAL Scan Post-hoc Analyses. Rheumatol Ther. 2018 May 14. PMID: 29761420.
      View in: PubMed
    4. Mease PJ, Karki C, Liu M, Kavanaugh A, Ritchlin CT, Huynh DH, Palmer JB, Greenberg JD. Baseline patient characteristics associated with response to biologic therapy in patients with psoriatic arthritis enrolled in the Corrona Psoriatic Arthritis/Spondyloarthritis Registry. RMD Open. 2018; 4(1):e000638. PMID: 29707232.
      View in: PubMed
    5. Helliwell PS, Kavanaugh A. Radiographic Progression in Psoriatic Arthritis Achieving a Good Response to Treatment: Data Using Newer Composite Indices of Disease Activity. Arthritis Care Res (Hoboken). 2018 May; 70(5):797-800. PMID: 28834259.
      View in: PubMed
    6. van der Heijde D, Braun J, Rudwaleit M, Purcaru O, Kavanaugh A. Improvements in workplace and household productivity with certolizumab pegol treatment in axial spondyloarthritis: results to week 96 of a phase III study. RMD Open. 2018; 4(1):e000659. PMID: 29670761.
      View in: PubMed
    7. Genovese M, Westhovens R, Meuleners L, Van der Aa A, Harrison P, Tasset C, Kavanaugh A. Effect of filgotinib, a selective JAK 1 inhibitor, with and without methotrexate in patients with rheumatoid arthritis: patient-reported outcomes. Arthritis Res Ther. 2018 Mar 23; 20(1):57. PMID: 29566740.
      View in: PubMed
    8. Gulati AM, Salvesen Ø, Thomsen RS, Kavanaugh A, Semb AG, Rollefstad S, Haugeberg G, Hoff M. Change in cardiovascular risk factors in patients who develop psoriatic arthritis: longitudinal data from the Nord-Trøndelag Health Study (HUNT). RMD Open. 2018; 4(1):e000630. PMID: 29556420.
      View in: PubMed
    9. Smolen JS, Aletaha D, Barton A, Burmester GR, Emery P, Firestein GS, Kavanaugh A, McInnes IB, Solomon DH, Strand V, Yamamoto K. Rheumatoid arthritis. Nat Rev Dis Primers. 2018 Feb 08; 4:18001. PMID: 29417936.
      View in: PubMed
    10. Coates LC, FitzGerald O, Merola JF, Smolen J, van Mens LJJ, Bertheussen H, Boehncke WH, Callis Duffin K, Campbell W, de Wit M, Gladman D, Gottlieb A, James J, Kavanaugh A, Kristensen LE, Kvien TK, Luger T, McHugh N, Mease P, Nash P, Ogdie A, Rosen CF, Strand V, Tillett W, Veale DJ, Helliwell PS. Group for Research and Assessment of Psoriasis and Psoriatic Arthritis/Outcome Measures in Rheumatology Consensus-Based Recommendations and Research Agenda for Use of Composite Measures and Treatment Targets in Psoriatic Arthritis. Arthritis Rheumatol. 2018 Mar; 70(3):345-355. PMID: 29193765.
      View in: PubMed
    11. Smith CJF, Jones KL, Johnson DL, Bandoli G, Robinson LK, Kavanaugh A, Chambers CD. Risk of infantile hemangiomas in the offspring of women with autoimmune disease and the pathogenic implications of these lesions. Am J Med Genet A. 2018 Mar; 176(3):570-577. PMID: 29341431.
      View in: PubMed
    12. Chen B, Zhao Y, Cheng X, Ma Y, Chang EY, Kavanaugh A, Liu S, Du J. Three-dimensional ultrashort echo time cones (3D UTE-Cones) magnetic resonance imaging of entheses and tendons. Magn Reson Imaging. 2018 Jun; 49:4-9. PMID: 29309823.
      View in: PubMed
    13. Kavanaugh A. Rheumatoid arthritis: Do TNF inhibitors influence lymphoma development? Nat Rev Rheumatol. 2017 Nov 21; 13(12):697-698. PMID: 29158571.
      View in: PubMed
    14. Kavanaugh A, van Vollenhoven RF, Fleischmann R, Emery P, Sainsbury I, Florentinus S, Chen S, Guérette B, Kupper H, Smolen JS. Testing treat-to-target outcomes with initial methotrexate monotherapy compared with initial tumour necrosis factor inhibitor (adalimumab) plus methotrexate in early rheumatoid arthritis. Ann Rheum Dis. 2018 Feb; 77(2):289-292. PMID: 29146743.
      View in: PubMed
    15. Coates LC, Tillett W, Shaddick G, Pincus T, Kavanaugh A, Helliwell PS. Value of RAPID3 in patients with PsA: results from the TICOPA and LOPAS II databases. Arthritis Care Res (Hoboken). 2017 Nov 07. PMID: 29112801.
      View in: PubMed
    16. Mease PJ, Karki C, Palmer JB, Etzel CJ, Kavanaugh A, Ritchlin CT, Malley W, Herrera V, Tran M, Greenberg JD. Clinical Characteristics, Disease Activity, and Patient-Reported Outcomes in Psoriatic Arthritis Patients With Dactylitis or Enthesitis: Results From the Corrona Psoriatic Arthritis/Spondyloarthritis Registry. Arthritis Care Res (Hoboken). 2017 Nov; 69(11):1692-1699. PMID: 28376239.
      View in: PubMed
    17. Kavanaugh A, Husni ME, Harrison DD, Kim L, Lo KH, Leu JH, Hsia EC. Safety and Efficacy of Intravenous Golimumab in Patients With Active Psoriatic Arthritis: Results Through Week Twenty-Four of the GO-VIBRANT Study. Arthritis Rheumatol. 2017 11; 69(11):2151-2161. PMID: 28805045.
      View in: PubMed
    18. Keystone EC, Breedveld FC, van der Heijde D, van Vollenhoven RF, Emery P, Smolen JS, Sainsbury I, Florentinus S, Kupper H, Chen K, Kavanaugh A. Achieving comprehensive disease control in patients with early and established rheumatoid arthritis treated with adalimumab plus methotrexate versus methotrexate alone. RMD Open. 2017; 3(2):e000445. PMID: 29018564.
      View in: PubMed
    19. Burmester GR, Kaeley GS, Kavanaugh A, Gabay C, MacCarter DK, Nash P, Takeuchi T, Goss SL, Rodila R, Chen K, Kupper H, Kalabic J. Treatment efficacy and methotrexate-related toxicity in patients with rheumatoid arthritis receiving methotrexate in combination with adalimumab. RMD Open. 2017; 3(2):e000465. PMID: 28955494.
      View in: PubMed
    20. Strand V, Michalska M, Birchwood C, Pei J, Tuckwell K, Finch R, Gabay C, Kavanaugh A, Jones G. Impact of tocilizumab monotherapy on patient-reported outcomes in patients with rheumatoid arthritis from two randomised controlled trials. RMD Open. 2017; 3(2):e000496. PMID: 28955499.
      View in: PubMed
    21. Calabrese LH, Kavanaugh A, Yeo AE, Lipsky PE. Frequency, distribution and immunologic nature of infusion reactions in subjects receiving pegloticase for chronic refractory gout. Arthritis Res Ther. 2017 Aug 17; 19(1):191. PMID: 28818095.
      View in: PubMed
    22. Michelsen B, Diamantopoulos AP, Soldal DM, Hammer HB, Kavanaugh A, Haugeberg G. Achilles enthesitis defined by ultrasound is not associated with clinical enthesitis in patients with psoriatic arthritis. RMD Open. 2017; 3(2):e000486. PMID: 28879054.
      View in: PubMed
    23. Coates LC, Gossec L, Ramiro S, Mease P, van der Heijde D, Smolen JS, Ritchlin C, Kavanaugh A. New GRAPPA and EULAR recommendations for the management of psoriatic arthritis. Rheumatology (Oxford). 2017 08 01; 56(8):1251-1253. PMID: 28077693.
      View in: PubMed
    24. Mease PJ, Kavanaugh A, Coates LC, McInnes IB, Hojnik M, Zhang Y, Anderson JK, Dorr AP, Gladman DD. Prediction and benefits of minimal disease activity in patients with psoriatic arthritis and active skin disease in the ADEPT trial. RMD Open. 2017; 3(1):e000415. PMID: 29225916.
      View in: PubMed
    25. Gulati AM, Hoff M, Salvesen Ø, Dhainaut A, Semb AG, Kavanaugh A, Haugeberg G. Bone mineral density in patients with psoriatic arthritis: data from the Nord-Trøndelag Health Study 3. RMD Open. 2017; 3(1):e000413. PMID: 28955483.
      View in: PubMed
    26. Smolen JS, Schöls M, Braun J, Dougados M, FitzGerald O, Gladman DD, Kavanaugh A, Landewé R, Mease P, Sieper J, Stamm T, Wit M, Aletaha D, Baraliakos X, Betteridge N, Bosch FVD, Coates LC, Emery P, Gensler LS, Gossec L, Helliwell P, Jongkees M, Kvien TK, Inman RD, McInnes IB, Maccarone M, Machado PM, Molto A, Ogdie A, Poddubnyy D, Ritchlin C, Rudwaleit M, Tanew A, Thio B, Veale D, Vlam K, van der Heijde D. Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force. Ann Rheum Dis. 2018 01; 77(1):3-17. PMID: 28684559.
      View in: PubMed
    27. Kavanaugh A, Keystone E, Greenberg JD, Reed GW, Griffith JM, Friedman AW, Saunders KC, Ganguli A. Benefit of biologics initiation in moderate versus severe rheumatoid arthritis: evidence from a United States registry. Rheumatology (Oxford). 2017 07 01; 56(7):1095-1101. PMID: 28340006.
      View in: PubMed
    28. Mease PJ, Karki C, Palmer JB, Etzel CJ, Kavanaugh A, Ritchlin CT, Malley W, Herrera V, Tran M, Greenberg JD. Clinical and Patient-reported Outcomes in Patients with Psoriatic Arthritis (PsA) by Body Surface Area Affected by Psoriasis: Results from the Corrona PsA/Spondyloarthritis Registry. J Rheumatol. 2017 Aug; 44(8):1151-1158. PMID: 28620063.
      View in: PubMed
    29. Jadon DR, Gladman DD, Mease PJ, FitzGerald O, Chandran V, Goel N, Rosen CF, Maksymowych WP, Ritchlin CT, Ogdie A, Coates LC, Cauli A, Soriano ER, Husni ME, Campbell W, Azevedo VF, Callis Duffin K, Armstrong AW, Gottlieb AB, Kavanaugh A, Garg A, Helliwell PS. Proceedings of the GRAPPA 2016 Retreat. J Rheumatol. 2017 May; 44(5):668-673. PMID: 28461522.
      View in: PubMed
    30. Coates LC, Chandran V, Ogdie A, O'Sullivan D, Brooke M, Steinkoenig I, Mease PJ, Ritchlin CT, Kavanaugh A. International Treatment Recommendations Update: A Report from the GRAPPA 2016 Annual Meeting. J Rheumatol. 2017 May; 44(5):684-685. PMID: 28461525.
      View in: PubMed
    31. Smith CJF, Friedlander SF, Guma M, Kavanaugh A, Chambers CD. Infantile Hemangiomas: An Updated Review on Risk Factors, Pathogenesis, and Treatment. Birth Defects Res. 2017 Jul 03; 109(11):809-815. PMID: 28402073.
      View in: PubMed
    32. Kavanaugh A, Mease PJ, Reimold AM, Tahir H, Rech J, Hall S, Geusens P, Wang Z, Pricop L, Mpofu S. Secukinumab for Long-Term Treatment of Psoriatic Arthritis: A Two-Year Followup From a Phase III, Randomized, Double-Blind Placebo-Controlled Study. Arthritis Care Res (Hoboken). 2017 Mar; 69(3):347-355. PMID: 27696786.
      View in: PubMed
    33. Michelsen B, Diamantopoulos AP, Høiberg HK, Soldal DM, Kavanaugh A, Haugeberg G. Need for Improvement in Current Treatment of Psoriatic Arthritis: Study of an Outpatient Clinic Population. J Rheumatol. 2017 Apr; 44(4):431-436. PMID: 28148701.
      View in: PubMed
    34. Gossec L, Coates LC, de Wit M, Kavanaugh A, Ramiro S, Mease PJ, Ritchlin CT, van der Heijde D, Smolen JS. Management of psoriatic arthritis in 2016: a comparison of EULAR and GRAPPA recommendations. Nat Rev Rheumatol. 2016 Dec; 12(12):743-750. PMID: 27829672.
      View in: PubMed
    35. Rahman P, Puig L, Gottlieb AB, Kavanaugh A, McInnes IB, Ritchlin C, Li S, Wang Y, Song M, Mendelsohn A, Han C. Ustekinumab Treatment and Improvement of Physical Function and Health-Related Quality of Life in Patients With Psoriatic Arthritis. Arthritis Care Res (Hoboken). 2016 Dec; 68(12):1812-1822. PMID: 27483458.
      View in: PubMed
    36. Pincus T, Braun J, Kavanaugh A, Ravelli A, Smolen JS. Information technology in rheumatology. Clin Exp Rheumatol. 2016 Sep-Oct; 34(5 Suppl 101):1. PMID: 27762207.
      View in: PubMed
    37. Chang EY, Chen KC, Huang BK, Kavanaugh A. Adult Inflammatory Arthritides: What the Radiologist Should Know. Radiographics. 2016 Oct; 36(6):1849-1870. PMID: 27726745.
      View in: PubMed
    38. Martin G, Strober BE, Leonardi CL, Gelfand JM, Blauvelt A, Kavanaugh A, Stein Gold L, Berman B, Rosen T, Stockfleth E. Updates on Psoriasis and Cutaneous Oncology: Proceedings from the 2016 MauiDerm Meeting based on presentations by. J Clin Aesthet Dermatol. 2016 Sep; 9(9 Suppl 1):S5-S29. PMID: 27800119.
      View in: PubMed
    39. Baronaite Hansen R, Kavanaugh A. Secukinumab for the treatment of psoriatic arthritis. Expert Rev Clin Immunol. 2016 Oct; 12(10):1027-36. PMID: 27550397.
      View in: PubMed
    40. Sweeney SR, Kavanaugh A, Lodi A, Wang B, Boyle D, Tiziani S, Guma M. Metabolomic profiling predicts outcome of rituximab therapy in rheumatoid arthritis. RMD Open. 2016; 2(2):e000289. PMID: 27651926; PMCID: PMC5013418.
    41. Fleischmann RM, Huizinga TW, Kavanaugh A, Wilkinson B, Kwok K, DeMasi R, van Vollenhoven RF. Efficacy of tofacitinib monotherapy in methotrexate-naive patients with early or established rheumatoid arthritis. RMD Open. 2016; 2(2):e000262. PMID: 27493790; PMCID: PMC4964179.
    42. Kavanaugh A, McInnes IB, Mease PJ, Hall S, Chinoy H, Kivitz AJ, Wang Z, Mpofu S. Efficacy of Subcutaneous Secukinumab in Patients with Active Psoriatic Arthritis Stratified by Prior Tumor Necrosis Factor Inhibitor Use: Results from the Randomized Placebo-controlled FUTURE 2 Study. J Rheumatol. 2016 09; 43(9):1713-7. PMID: 27307536.
      View in: PubMed
    43. de Lautour H, Taylor WJ, Adebajo A, Alten R, Burgos-Vargas R, Chapman P, Cimmino MA, da Rocha Castelar Pinheiro G, Day R, Harrold LR, Helliwell P, Janssen M, Kerr G, Kavanaugh A, Khanna D, Khanna PP, Lin C, Louthrenoo W, McCarthy G, Vazquez-Mellado J, Mikuls TR, Neogi T, Ogdie A, Perez-Ruiz F, Schlesinger N, Ralph Schumacher H, Scirè CA, Singh JA, Sivera F, Slot O, Stamp LK, Tausche AK, Terkeltaub R, Uhlig T, van de Laar M, White D, Yamanaka H, Zeng X, Dalbeth N. Development of Preliminary Remission Criteria for Gout Using Delphi and 1000Minds Consensus Exercises. Arthritis Care Res (Hoboken). 2016 May; 68(5):667-72. PMID: 26414176.
      View in: PubMed
    44. Harrold LR, Reed GW, Kremer JM, Curtis JR, Solomon DH, Hochberg MC, Kavanaugh A, Saunders KC, Shan Y, Spruill TM, Pappas DA, Greenberg JD. Identifying factors associated with concordance with the American College of Rheumatology rheumatoid arthritis treatment recommendations. Arthritis Res Ther. 2016 Apr 26; 18:94. PMID: 27118040; PMCID: PMC4845312.
    45. Emery P, Smolen JS, Ganguli A, Meerwein S, Bao Y, Kupper H, Chen N, Kavanaugh A. Effect of adalimumab on the work-related outcomes scores in patients with early rheumatoid arthritis receiving methotrexate. Rheumatology (Oxford). 2016 08; 55(8):1458-65. PMID: 27114561.
      View in: PubMed
    46. Kavanaugh A, Puig L, Gottlieb AB, Ritchlin C, You Y, Li S, Song M, Randazzo B, Rahman P, McInnes IB. Efficacy and safety of ustekinumab in psoriatic arthritis patients with peripheral arthritis and physician-reported spondylitis: post-hoc analyses from two phase III, multicentre, double-blind, placebo-controlled studies (PSUMMIT-1/PSUMMIT-2). Ann Rheum Dis. 2016 Nov; 75(11):1984-1988. PMID: 27098404.
      View in: PubMed
    47. Michelsen B, Diamantopoulos AP, Hammer HB, Soldal DM, Kavanaugh A, Haugeberg G. Ultrasonographic evaluation in psoriatic arthritis is of major importance in evaluating disease activity. Ann Rheum Dis. 2016 Dec; 75(12):2108-2113. PMID: 27091837.
      View in: PubMed
    48. Coates LC, Kavanaugh A, Mease PJ, Soriano ER, Laura Acosta-Felquer M, Armstrong AW, Bautista-Molano W, Boehncke WH, Campbell W, Cauli A, Espinoza LR, FitzGerald O, Gladman DD, Gottlieb A, Helliwell PS, Husni ME, Love TJ, Lubrano E, McHugh N, Nash P, Ogdie A, Orbai AM, Parkinson A, O'Sullivan D, Rosen CF, Schwartzman S, Siegel EL, Toloza S, Tuong W, Ritchlin CT. Group for Research and Assessment of Psoriasis and Psoriatic Arthritis 2015 Treatment Recommendations for Psoriatic Arthritis. Arthritis Rheumatol. 2016 05; 68(5):1060-71. PMID: 26749174.
      View in: PubMed
    49. Kavanaugh A, Helliwell P, Ritchlin CT. Psoriatic Arthritis and Burden of Disease: Patient Perspectives from the Population-Based Multinational Assessment of Psoriasis and Psoriatic Arthritis (MAPP) Survey. Rheumatol Ther. 2016 Jun; 3(1):91-102. PMID: 27747516.
      View in: PubMed
    50. Lebwohl MG, Kavanaugh A, Armstrong AW, Van Voorhees AS. US Perspectives in the Management of Psoriasis and Psoriatic Arthritis: Patient and Physician Results from the Population-Based Multinational Assessment of Psoriasis and Psoriatic Arthritis (MAPP) Survey. Am J Clin Dermatol. 2016 Feb; 17(1):87-97. PMID: 26718712; PMCID: PMC4733141.
    51. Kavanaugh A, van der Heijde D, Beutler A, Gladman D, Mease P, Krueger GG, McInnes IB, Helliwell P, Coates LC, Xu S. Radiographic Progression of Patients With Psoriatic Arthritis Who Achieve Minimal Disease Activity in Response to Golimumab Therapy: Results Through 5 Years of a Randomized, Placebo-Controlled Study. Arthritis Care Res (Hoboken). 2016 Feb; 68(2):267-74. PMID: 25779603.
      View in: PubMed
    52. Her M, Kavanaugh A. Alterations in immune function with biologic therapies for autoimmune disease. J Allergy Clin Immunol. 2016 Jan; 137(1):19-27. PMID: 26768759.
      View in: PubMed
    53. Boyd T, Kavanaugh A. Novel approaches to biological therapy for psoriatic arthritis. Expert Opin Biol Ther. 2016; 16(2):173-86. PMID: 26572089.
      View in: PubMed
    54. Kavanaugh A, Puig L, Gottlieb AB, Ritchlin C, Li S, Wang Y, Mendelsohn AM, Song M, Zhu Y, Rahman P, McInnes IB. Maintenance of Clinical Efficacy and Radiographic Benefit Through Two Years of Ustekinumab Therapy in Patients With Active Psoriatic Arthritis: Results From a Randomized, Placebo-Controlled Phase III Trial. Arthritis Care Res (Hoboken). 2015 Dec; 67(12):1739-49. PMID: 26097039.
      View in: PubMed
    55. Gabay C, McInnes IB, Kavanaugh A, Tuckwell K, Klearman M, Pulley J, Sattar N. Comparison of lipid and lipid-associated cardiovascular risk marker changes after treatment with tocilizumab or adalimumab in patients with rheumatoid arthritis. Ann Rheum Dis. 2016 Oct; 75(10):1806-12. PMID: 26613768.
      View in: PubMed
    56. Singh JA, Saag KG, Bridges SL, Akl EA, Bannuru RR, Sullivan MC, Vaysbrot E, McNaughton C, Osani M, Shmerling RH, Curtis JR, Furst DE, Parks D, Kavanaugh A, O'Dell J, King C, Leong A, Matteson EL, Schousboe JT, Drevlow B, Ginsberg S, Grober J, St Clair EW, Tindall E, Miller AS, McAlindon T. 2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. Arthritis Care Res (Hoboken). 2016 Jan; 68(1):1-25. PMID: 26545825.
      View in: PubMed
    57. Singh JA, Saag KG, Bridges SL, Akl EA, Bannuru RR, Sullivan MC, Vaysbrot E, McNaughton C, Osani M, Shmerling RH, Curtis JR, Furst DE, Parks D, Kavanaugh A, O'Dell J, King C, Leong A, Matteson EL, Schousboe JT, Drevlow B, Ginsberg S, Grober J, St Clair EW, Tindall E, Miller AS, McAlindon T. 2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. Arthritis Rheumatol. 2016 Jan; 68(1):1-26. PMID: 26545940.
      View in: PubMed
    58. Yoshida K, Radner H, Mjaavatten MD, Greenberg JD, Kavanaugh A, Kishimoto M, Matsui K, Okada M, Reed G, Saeki Y, Tohma S, Kremer J, Solomon DH. Incidence and Predictors of Biological Antirheumatic Drug Discontinuation Attempts among Patients with Rheumatoid Arthritis in Remission: A CORRONA and NinJa Collaborative Cohort Study. J Rheumatol. 2015 Dec; 42(12):2238-46. PMID: 26523025.
      View in: PubMed
    59. Lubrano E, Perrotta FM, Kavanaugh A. An overview of low disease activity and remission in psoriatic arthritis. Clin Exp Rheumatol. 2015 Sep-Oct; 33(5 Suppl 93):S51-4. PMID: 26470835.
      View in: PubMed
    60. Boyd T, Kavanaugh A. Interleukin-17 inhibition in psoriatic arthritis. Clin Exp Rheumatol. 2015 Sep-Oct; 33(5 Suppl 93):S119-23. PMID: 26471234.
      View in: PubMed
    61. Kavanaugh A, Boyd T. Trial design in psoriatic arthritis: what could be changed? Clin Exp Rheumatol. 2015 Jul-Aug; 33(4 Suppl 92):S15-8. PMID: 26458015.
      View in: PubMed
    62. Mease PJ, McInnes IB, Kirkham B, Kavanaugh A, Rahman P, van der Heijde D, Landewé R, Nash P, Pricop L, Yuan J, Richards HB, Mpofu S. Secukinumab Inhibition of Interleukin-17A in Patients with Psoriatic Arthritis. N Engl J Med. 2015 Oct; 373(14):1329-39. PMID: 26422723.
      View in: PubMed
    63. Boyd T, Kavanaugh A. Clinical guidelines: Addressing comorbidities in systemic inflammatory disorders. Nat Rev Rheumatol. 2015 Dec; 11(12):689-91. PMID: 26390846.
      View in: PubMed
    64. Smolen JS, van Vollenhoven R, Kavanaugh A, Strand V, Vencovsky J, Schiff M, Landewé R, Haraoui B, Arendt C, Mountian I, Carter D, van der Heijde D. Certolizumab pegol plus methotrexate 5-year results from the rheumatoid arthritis prevention of structural damage (RAPID) 2 randomized controlled trial and long-term extension in rheumatoid arthritis patients. Arthritis Res Ther. 2015 Sep 10; 17:245. PMID: 26353833; PMCID: PMC4565002.
    65. Desai SR, Frieden IJ, Gelfand JM, High W, Kavanaugh A, Marghoob AA, Ozog DM, Rosen T, Stein Gold L, Strober B, Swanson N, Martin G. Updates on Psoriasis and Cutaneous Oncology: Proceedings from the 2015 MauiDerm Meeting. J Clin Aesthet Dermatol. 2015 Sep; 8(9 Suppl):S4-S26. PMID: 26504503; PMCID: PMC4591555.
    66. Boyd T, Kavanaugh A. Novel Treatment Concepts in Psoriatic Arthritis. Rheum Dis Clin North Am. 2015 Nov; 41(4):739-54. PMID: 26476230.
      View in: PubMed
    67. Kavanaugh A, Cush JJ. Pregnancy: Data, Outcomes, and Treatment Paradigms in Rheumatology. J Rheumatol. 2015 Aug; 42(8):1357-8. PMID: 26233947.
      View in: PubMed
    68. Furst DE, Kavanaugh A, Florentinus S, Kupper H, Karunaratne M, Birbara CA. Final 10-year effectiveness and safety results from study DE020: adalimumab treatment in patients with rheumatoid arthritis and an inadequate response to standard therapy. Rheumatology (Oxford). 2015 Dec; 54(12):2188-97. PMID: 26199453.
      View in: PubMed
    69. Kang EJ, Kavanaugh A. Psoriatic arthritis: latest treatments and their place in therapy. Ther Adv Chronic Dis. 2015 Jul; 6(4):194-203. PMID: 26137209; PMCID: PMC4480547.
    70. McInnes IB, Mease PJ, Kirkham B, Kavanaugh A, Ritchlin CT, Rahman P, van der Heijde D, Landewé R, Conaghan PG, Gottlieb AB, Richards H, Pricop L, Ligozio G, Patekar M, Mpofu S. Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2015 Sep 19; 386(9999):1137-46. PMID: 26135703.
      View in: PubMed
    71. Das S, Huynh D, Yang H, Ceponis A, Kavanaugh A. Salivary Gland Ultrasonography as a Diagnostic Tool for Secondary Sjögren Syndrome in Rheumatoid Arthritis. J Rheumatol. 2015 Jul; 42(7):1119-22. PMID: 25934827.
      View in: PubMed
    72. Her M, Kavanaugh A. Advances in use of immunomodulatory agents--a rheumatology perspective. Nat Rev Gastroenterol Hepatol. 2015 Jun; 12(6):363-8. PMID: 25895821.
      View in: PubMed
    73. Michelsen B, Fiane R, Diamantopoulos AP, Soldal DM, Hansen IJ, Sokka T, Kavanaugh A, Haugeberg G. A comparison of disease burden in rheumatoid arthritis, psoriatic arthritis and axial spondyloarthritis. PLoS One. 2015; 10(4):e0123582. PMID: 25853482; PMCID: PMC4390320.
    74. Van den Bosch F, Kavanaugh A, Kron M, Kupper H, Mease PJ. Clinical remission in patients with active psoriatic arthritis treated with adalimumab and correlations in joint and skin manifestations. J Rheumatol. 2015 Jun; 42(6):952-9. PMID: 25834212.
      View in: PubMed
    75. Busa S, Kavanaugh A. Drug safety evaluation of apremilast for treating psoriatic arthritis. Expert Opin Drug Saf. 2015 Jun; 14(6):979-85. PMID: 25827658.
      View in: PubMed
    76. Gulati AM, Semb AG, Rollefstad S, Romundstad PR, Kavanaugh A, Gulati S, Haugeberg G, Hoff M. On the HUNT for cardiovascular risk factors and disease in patients with psoriatic arthritis: population-based data from the Nord-Trøndelag Health Study. Ann Rheum Dis. 2016 May; 75(5):819-24. PMID: 25814652.
      View in: PubMed
    77. Kavanaugh A, Cush JJ, Ahmed MS, Bermas BL, Chakravarty E, Chambers C, Clowse M, Curtis JR, Dao K, Hankins GD, Koren G, Kim SC, Lapteva L, Mahadevan U, Moore T, Nolan M, Ren Z, Sammaritano LR, Seymour S, Weisman MH. Proceedings from the American College of Rheumatology Reproductive Health Summit: the management of fertility, pregnancy, and lactation in women with autoimmune and systemic inflammatory diseases. Arthritis Care Res (Hoboken). 2015 Mar; 67(3):313-25. PMID: 25385050.
      View in: PubMed
    78. Hansen RB, Kavanaugh A. Certolizumab pegol for the treatment of psoriatic arthritis. Expert Rev Clin Immunol. 2015 Mar; 11(3):307-18. PMID: 25651776.
      View in: PubMed
    79. Kavanaugh A, Mease PJ, Gomez-Reino JJ, Adebajo AO, Wollenhaupt J, Gladman DD, Hochfeld M, Teng LL, Schett G, Lespessailles E, Hall S. Longterm (52-week) results of a phase III randomized, controlled trial of apremilast in patients with psoriatic arthritis. J Rheumatol. 2015 Mar; 42(3):479-88. PMID: 25593233.
      View in: PubMed
    80. Kavanaugh A, Lee SJ, Curtis JR, Greenberg JD, Kremer JM, Soto L, Etzel CJ, Cox V, Yoshida K, Reed GW, Solomon DH. Discontinuation of tumour necrosis factor inhibitors in patients with rheumatoid arthritis in low-disease activity: persistent benefits. Data from the Corrona registry. Ann Rheum Dis. 2015 Jun; 74(6):1150-5. PMID: 25471471.
      View in: PubMed
    81. Helliwell P, Coates L, Chandran V, Gladman D, de Wit M, FitzGerald O, Kavanaugh A, Strand V, Mease PJ, Boehncke WH, Langley RG, Lubrano E, Maccarone M, Schulze-Koops H, Miceli-Richard C, Queiro R. Qualifying unmet needs and improving standards of care in psoriatic arthritis. Arthritis Care Res (Hoboken). 2014 Dec; 66(12):1759-66. PMID: 25047391; PMCID: PMC4282108.
    82. Weinblatt ME, Genovese MC, Ho M, Hollis S, Rosiak-Jedrychowicz K, Kavanaugh A, Millson DS, Leon G, Wang M, van der Heijde D. Effects of fostamatinib, an oral spleen tyrosine kinase inhibitor, in rheumatoid arthritis patients with an inadequate response to methotrexate: results from a phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Arthritis Rheumatol. 2014 Dec; 66(12):3255-64. PMID: 25223724.
      View in: PubMed
    83. Coates LC, Kavanaugh A, Ritchlin CT. Systematic review of treatments for psoriatic arthritis: 2014 update for the GRAPPA. J Rheumatol. 2014 Nov; 41(11):2273-6. PMID: 25362710.
      View in: PubMed
    84. Armstrong AW, Tuong W, Love TJ, Carneiro S, Grynszpan R, Lee SS, Kavanaugh A. Treatments for nail psoriasis: a systematic review by the GRAPPA Nail Psoriasis Work Group. J Rheumatol. 2014 Nov; 41(11):2306-14. PMID: 25362716.
      View in: PubMed
    85. Genovese MC, van der Heijde DM, Keystone EC, Spindler AJ, Benhamou C, Kavanaugh A, Fudman E, Lampl K, O'Brien C, Duffield EL, Poiley J, Weinblatt ME. A phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study of 2 dosing regimens of fostamatinib in patients with rheumatoid arthritis with an inadequate response to a tumor necrosis factor-a antagonist. J Rheumatol. 2014 Nov; 41(11):2120-8. PMID: 25225285.
      View in: PubMed
    86. Emery P, Kavanaugh A, Bao Y, Ganguli A, Mulani P. Comprehensive disease control (CDC): what does achieving CDC mean for patients with rheumatoid arthritis? Ann Rheum Dis. 2015 Dec; 74(12):2165-74. PMID: 25139667; PMCID: PMC4680119.
    87. Huynh D, Kavanaugh A. Psoriatic arthritis: current therapy and future approaches. Rheumatology (Oxford). 2015 Jan; 54(1):20-8. PMID: 25125588.
      View in: PubMed
    88. Landewé RB, Smolen JS, Weinblatt ME, Emery P, Dougados M, Fleischmann R, Aletaha D, Kavanaugh A, van der Heijde D. Can we improve the performance and reporting of investigator-initiated clinical trials? Rheumatoid arthritis as an example. Ann Rheum Dis. 2014 Oct; 73(10):1755-60. PMID: 25114058.
      View in: PubMed
    89. Her M, Kavanaugh A. A review of disease activity measures for psoriatic arthritis: what is the best approach? Expert Rev Clin Immunol. 2014 Sep; 10(9):1241-54. PMID: 25088300.
      View in: PubMed
    90. van Laar JM, Kavanaugh A. Concepts of pathogenesis and emerging treatments for inflammatory arthritis. Best Pract Res Clin Rheumatol. 2014 Aug; 28(4):537-8. PMID: 25481547.
      View in: PubMed
    91. Coates LC, Ritchlin CT, Kavanaugh A. GRAPPA treatment recommendations: an update from the GRAPPA 2013 Annual Meeting. J Rheumatol. 2014 Jun; 41(6):1237-9. PMID: 24882861.
      View in: PubMed
    92. Helliwell PS, Kavanaugh A. Comparison of composite measures of disease activity in psoriatic arthritis using data from an interventional study with golimumab. Arthritis Care Res (Hoboken). 2014 May; 66(5):749-56. PMID: 24127416.
      View in: PubMed
    93. Cush JJ, Kavanaugh A. Editorial: pregnancy and rheumatoid arthritis - do not let the perfect become the enemy of the good. Curr Opin Rheumatol. 2014 May; 26(3):299-301. PMID: 24667288.
      View in: PubMed
    94. Dennis G, Holweg CT, Kummerfeld SK, Choy DF, Setiadi AF, Hackney JA, Haverty PM, Gilbert H, Lin WY, Diehl L, Fischer S, Song A, Musselman D, Klearman M, Gabay C, Kavanaugh A, Endres J, Fox DA, Martin F, Townsend MJ. Synovial phenotypes in rheumatoid arthritis correlate with response to biologic therapeutics. Arthritis Res Ther. 2014; 16(2):R90. PMID: 25167216; PMCID: PMC4060385.
    95. Kavanaugh A, McInnes IB, Mease P, Krueger GG, Gladman D, van der Heijde D, Zhou Y, Lu J, Leu JH, Goldstein N, Beutler A. Clinical efficacy, radiographic and safety findings through 5 years of subcutaneous golimumab treatment in patients with active psoriatic arthritis: results from a long-term extension of a randomised, placebo-controlled trial (the GO-REVEAL study). Ann Rheum Dis. 2014 Sep; 73(9):1689-94. PMID: 24748630; PMCID: PMC4145441.
    96. Kavanaugh A, Wells AF. Benefits and risks of low-dose glucocorticoid treatment in the patient with rheumatoid arthritis. Rheumatology (Oxford). 2014 Oct; 53(10):1742-51. PMID: 24729402; PMCID: PMC4165844.
    97. Lipsky PE, Calabrese LH, Kavanaugh A, Sundy JS, Wright D, Wolfson M, Becker MA. Pegloticase immunogenicity: the relationship between efficacy and antibody development in patients treated for refractory chronic gout. Arthritis Res Ther. 2014 Mar 04; 16(2):R60. PMID: 24588936; PMCID: PMC4060440.
    98. Kavanaugh A, Mease PJ, Gomez-Reino JJ, Adebajo AO, Wollenhaupt J, Gladman DD, Lespessailles E, Hall S, Hochfeld M, Hu C, Hough D, Stevens RM, Schett G. Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor. Ann Rheum Dis. 2014 Jun; 73(6):1020-6. PMID: 24595547; PMCID: PMC4033106.
    99. Lebwohl MG, Bachelez H, Barker J, Girolomoni G, Kavanaugh A, Langley RG, Paul CF, Puig L, Reich K, van de Kerkhof PC. Patient perspectives in the management of psoriasis: results from the population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis Survey. J Am Acad Dermatol. 2014 May; 70(5):871-81.e1-30. PMID: 24576585.
      View in: PubMed
    100. Kavanaugh A, Ritchlin C, Rahman P, Puig L, Gottlieb AB, Li S, Wang Y, Noonan L, Brodmerkel C, Song M, Mendelsohn AM, McInnes IB. Ustekinumab, an anti-IL-12/23 p40 monoclonal antibody, inhibits radiographic progression in patients with active psoriatic arthritis: results of an integrated analysis of radiographic data from the phase 3, multicentre, randomised, double-blind, placebo-controlled PSUMMIT-1 and PSUMMIT-2 trials. Ann Rheum Dis. 2014 Jun; 73(6):1000-6. PMID: 24553909; PMCID: PMC4033146.
    101. Ceponis A, Onishi M, Bluestein HG, Kalunian K, Townsend J, Kavanaugh A. Utility of the ultrasound examination of the hand and wrist joints in the management of established rheumatoid arthritis. Arthritis Care Res (Hoboken). 2014 Feb; 66(2):236-44. PMID: 23983173.
      View in: PubMed
    102. Kirkham BW, Kavanaugh A, Reich K. Interleukin-17A: a unique pathway in immune-mediated diseases: psoriasis, psoriatic arthritis and rheumatoid arthritis. Immunology. 2014 Feb; 141(2):133-42. PMID: 23819583; PMCID: PMC3904234.
    103. Ritchlin C, Rahman P, Kavanaugh A, McInnes IB, Puig L, Li S, Wang Y, Shen YK, Doyle MK, Mendelsohn AM, Gottlieb AB. Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trial. Ann Rheum Dis. 2014 Jun; 73(6):990-9. PMID: 24482301; PMCID: PMC4033144.
    104. Hansen RB, Kavanaugh A. Novel treatments with small molecules in psoriatic arthritis. Curr Rheumatol Rep. 2014; 16(9):443. PMID: 25027606.
      View in: PubMed
    105. Kay J, Fleischmann R, Keystone E, Hsia EC, Hsu B, Mack M, Goldstein N, Braun J, Kavanaugh A. Golimumab 3-year safety update: an analysis of pooled data from the long-term extensions of randomised, double-blind, placebo-controlled trials conducted in patients with rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis. Ann Rheum Dis. 2015 Mar; 74(3):538-46. PMID: 24344160; PMCID: PMC4345908.
    106. Keystone EC, Haraoui B, Guérette B, Mozaffarian N, Liu S, Kavanaugh A. Clinical, functional, and radiographic implications of time to treatment response in patients with early rheumatoid arthritis: a posthoc analysis of the PREMIER study. J Rheumatol. 2014 Feb; 41(2):235-43. PMID: 24293583.
      View in: PubMed
    107. Keystone EC, Breedveld FC, van der Heijde D, Landewé R, Florentinus S, Arulmani U, Liu S, Kupper H, Kavanaugh A. Longterm effect of delaying combination therapy with tumor necrosis factor inhibitor in patients with aggressive early rheumatoid arthritis: 10-year efficacy and safety of adalimumab from the randomized controlled PREMIER trial with open-label extension. J Rheumatol. 2014 Jan; 41(1):5-14. PMID: 24241487.
      View in: PubMed
    108. Smolen JS, Emery P, Fleischmann R, van Vollenhoven RF, Pavelka K, Durez P, Guérette B, Kupper H, Redden L, Arora V, Kavanaugh A. Adjustment of therapy in rheumatoid arthritis on the basis of achievement of stable low disease activity with adalimumab plus methotrexate or methotrexate alone: the randomised controlled OPTIMA trial. Lancet. 2014 Jan 25; 383(9914):321-32. PMID: 24168956.
      View in: PubMed
    109. Yoshida K, Sung YK, Kavanaugh A, Bae SC, Weinblatt ME, Kishimoto M, Matsui K, Tohma S, Solomon DH. Response to: 'Biologic discontinuation studies: a systematic review of methods' by van der Maas et al. Ann Rheum Dis. 2014 Jan; 73(1):e5. PMID: 24152418.
      View in: PubMed
    110. Pincus T, Braun J, Kavanaugh A, Smolen JS. Possible discontinuation of therapies in inflammatory rheumatic diseases - as with initiation of therapies, a shared decision between patient and rheumatologist. Clin Exp Rheumatol. 2013 Jul-Aug; 31(4 Suppl 78):S1-3. PMID: 24129127.
      View in: PubMed
    111. Yoshida K, Radner H, Kavanaugh A, Sung YK, Bae SC, Kishimoto M, Matsui K, Okada M, Tohma S, Weinblatt ME, Solomon DH. Use of data from multiple registries in studying biologic discontinuation: challenges and opportunities. Clin Exp Rheumatol. 2013 Jul-Aug; 31(4 Suppl 78):S28-32. PMID: 24129133; PMCID: PMC4843121.
    112. Kavanaugh A, Smolen JS. The when and how of biologic agent withdrawal in rheumatoid arthritis: learning from large randomised controlled trials. Clin Exp Rheumatol. 2013 Jul-Aug; 31(4 Suppl 78):S19-21. PMID: 24129131.
      View in: PubMed
    113. Kavanaugh A, McInnes IB, Krueger GG, Gladman D, Beutler A, Gathany T, Mack M, Tandon N, Han C, Mease P. Patient-reported outcomes and the association with clinical response in patients with active psoriatic arthritis treated with golimumab: findings through 2 years of a phase III, multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Care Res (Hoboken). 2013 Oct; 65(10):1666-73. PMID: 23666608; PMCID: PMC4282022.
    114. Bouguen G, Levesque BG, Feagan BG, Kavanaugh A, Peyrin-Biroulet L, Colombel JF, Hanauer SB, Sandborn WJ. Treat to target: a proposed new paradigm for the management of Crohn's disease. Clin Gastroenterol Hepatol. 2015 Jun; 13(6):1042-50.e2. PMID: 24036054.
      View in: PubMed
    115. Blauvelt A, Brown M, Gordon KB, Kavanaugh A, Leonardi CT, Stockfleth E, Strober B, Swanson NA, Martin G. Updates on Psoriasis and Cutaneous Oncology: Proceedings from the 2013 MauiDerm Meeting. J Clin Aesthet Dermatol. 2013 Sep; 6(9 Suppl):S2-S20. PMID: 24167640; PMCID: PMC3809592.
    116. Yang H, Kavanaugh A. Adverse effects of golimumab in the treatment of rheumatologic diseases. Expert Opin Drug Saf. 2014 Jan; 13(1):103-12. PMID: 23984970.
      View in: PubMed
    117. Hoff M, Gulati AM, Romundstad PR, Kavanaugh A, Haugeberg G. Prevalence and incidence rates of psoriatic arthritis in central Norway: data from the Nord-Trøndelag health study (HUNT). Ann Rheum Dis. 2015 Jan; 74(1):60-4. PMID: 23962458.
      View in: PubMed
    118. Gabay C, Kavanaugh A. Tocilizumab versus adalimumab for rheumatoid arthritis - Authors' reply. Lancet. 2013 Aug 03; 382(9890):395. PMID: 23911377.
      View in: PubMed
    119. Furst DE, Kay J, Wasko MC, Keystone E, Kavanaugh A, Deodhar A, Murphy FT, Magnus JH, Hsia EC, Hsu B, Xu S, Rahman MU, Doyle MK. The effect of golimumab on haemoglobin levels in patients with rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis. Rheumatology (Oxford). 2013 Oct; 52(10):1845-55. PMID: 23838027; PMCID: PMC3775295.
    120. Huynh D, Kavanaugh A. Psoriatic arthritis: current therapy and future directions. Expert Opin Pharmacother. 2013 Sep; 14(13):1755-64. PMID: 23815157.
      View in: PubMed
    121. Her M, Kavanaugh A. Treatment of spondyloarthropathy: the potential for agents other than TNF inhibitors. Curr Opin Rheumatol. 2013 Jul; 25(4):455-9. PMID: 23680779.
      View in: PubMed
    122. Keystone EC, van der Heijde D, Kavanaugh A, Kupper H, Liu S, Guérette B, Mozaffarian N. Clinical, functional, and radiographic benefits of longterm adalimumab plus methotrexate: final 10-year data in longstanding rheumatoid arthritis. J Rheumatol. 2013 Sep; 40(9):1487-97. PMID: 23818718.
      View in: PubMed
    123. Hoff M, Kavanaugh A, Haugeberg G. Hand bone loss in patients with psoriatic arthritis: posthoc analysis of IMPACT II data comparing infliximab and placebo. J Rheumatol. 2013 Aug; 40(8):1344-8. PMID: 23772084.
      View in: PubMed
    124. McInnes IB, Kavanaugh A, Gottlieb AB, Puig L, Rahman P, Ritchlin C, Brodmerkel C, Li S, Wang Y, Mendelsohn AM, Doyle MK. Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial. Lancet. 2013 Aug 31; 382(9894):780-9. PMID: 23769296.
      View in: PubMed
    125. Smolen JS, Braun J, Dougados M, Emery P, Fitzgerald O, Helliwell P, Kavanaugh A, Kvien TK, Landewé R, Luger T, Mease P, Olivieri I, Reveille J, Ritchlin C, Rudwaleit M, Schoels M, Sieper J, Wit Md, Baraliakos X, Betteridge N, Burgos-Vargas R, Collantes-Estevez E, Deodhar A, Elewaut D, Gossec L, Jongkees M, Maccarone M, Redlich K, van den Bosch F, Wei JC, Winthrop K, van der Heijde D. Treating spondyloarthritis, including ankylosing spondylitis and psoriatic arthritis, to target: recommendations of an international task force. Ann Rheum Dis. 2014 Jan; 73(1):6-16. PMID: 23749611; PMCID: PMC3888616.
    126. Kavanaugh A, Fleischmann R, Bergman MJ, Ruderman E, Troum O, Wells AF, Martin G, Calabrese LH, Gibofsky A, Strand V, Cush JJ. Proceedings of the 2013 Rheumatology Winter Clinical Symposia. Semin Arthritis Rheum. 2013 Jun; 42(6):667-73. PMID: 23731828.
      View in: PubMed
    127. Yoshida K, Sung YK, Kavanaugh A, Bae SC, Weinblatt ME, Kishimoto M, Matsui K, Tohma S, Solomon DH. Biologic discontinuation studies: a systematic review of methods. Ann Rheum Dis. 2014 Mar; 73(3):595-9. PMID: 23723316; PMCID: PMC4836605.
    128. Furst DE, Fleischman R, Kalden J, Kavanaugh A, Sieper J, Mease P, Smolen J, Breedveld F. Documentation of off-label use of biologics in Rheumatoid Arthritis. Ann Rheum Dis. 2013 Apr; 72 Suppl 2:ii35-51. PMID: 23532442.
      View in: PubMed
    129. Furst DE, Keystone EC, So AK, Braun J, Breedveld FC, Burmester GR, De Benedetti F, Dörner T, Emery P, Fleischmann R, Gibofsky A, Kalden JR, Kavanaugh A, Kirkham B, Mease P, Rubbert-Roth A, Sieper J, Singer NG, Smolen JS, Van Riel PL, Weisman MH, Winthrop KL. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2012. Ann Rheum Dis. 2013 Apr; 72 Suppl 2:ii2-34. PMID: 23532441.
      View in: PubMed
    130. Gabay C, Emery P, van Vollenhoven R, Dikranian A, Alten R, Pavelka K, Klearman M, Musselman D, Agarwal S, Green J, Kavanaugh A. Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial. Lancet. 2013 May 04; 381(9877):1541-50. PMID: 23515142.
      View in: PubMed
    131. Choy EH, Kavanaugh A, Jones SA. The problem of choice: current biologic agents and future prospects in RA. Nat Rev Rheumatol. 2013 Mar; 9(3):154-63. PMID: 23419427.
      View in: PubMed
    132. Prowse RL, Dalbeth N, Kavanaugh A, Adebajo AO, Gaffo AL, Terkeltaub R, Mandell BF, Suryana BP, Goldenstein-Schainberg C, Diaz-Torne C, Khanna D, Lioté F, Mccarthy G, Kerr GS, Yamanaka H, Janssens H, Baraf HF, Chen JH, Vazquez-Mellado J, Harrold LR, Stamp LK, Van De Laar MA, Janssen M, Doherty M, Boers M, Edwards NL, Gow P, Chapman P, Khanna P, Helliwell PS, Grainger R, Schumacher HR, Neogi T, Jansen TL, Louthrenoo W, Sivera F, Taylor WJ, Alten R. A delphi exercise to identify characteristic features of gout - opinions from patients and physicians, the first stage in developing new classification criteria. J Rheumatol. 2013 Apr; 40(4):498-505. PMID: 23418379.
      View in: PubMed
    133. Weinblatt ME, Kavanaugh A, Genovese MC, Jones DA, Musser TK, Grossbard EB, Magilavy DB. Effects of fostamatinib (R788), an oral spleen tyrosine kinase inhibitor, on health-related quality of life in patients with active rheumatoid arthritis: analyses of patient-reported outcomes from a randomized, double-blind, placebo-controlled trial. J Rheumatol. 2013 Apr; 40(4):369-78. PMID: 23378467.
      View in: PubMed
    134. Yazici Y, Curtis JR, Ince A, Baraf HS, Lepley DM, Devenport JN, Kavanaugh A. Early effects of tocilizumab in the treatment of moderate to severe active rheumatoid arthritis: a one-week sub-study of a randomised controlled trial (Rapid Onset and Systemic Efficacy [ROSE] Study). Clin Exp Rheumatol. 2013 May-Jun; 31(3):358-64. PMID: 23305631.
      View in: PubMed
    135. Turchetti G, Smolen JS, Kavanaugh A, Braun J, Pincus T, Bombardieri S. Treat-to-target in rheumatoid arthritis: clinical and pharmacoeconomic considerations. Introduction. Clin Exp Rheumatol. 2012 Jul-Aug; 30(4 Suppl 73):S1. PMID: 23168235.
      View in: PubMed
    136. Kavanaugh A, McInnes IB, Mease PJ, Krueger GG, Gladman DD, van der Heijde D, Mudivarthy S, Xu W, Mack M, Xu Z, Beutler A. Clinical efficacy, radiographic and safety findings through 2 years of golimumab treatment in patients with active psoriatic arthritis: results from a long-term extension of the randomised, placebo-controlled GO-REVEAL study. Ann Rheum Dis. 2013 Nov; 72(11):1777-85. PMID: 23161902; PMCID: PMC3812864.
    137. Kavanaugh A. Psoriatic arthritis: treat-to-target. Clin Exp Rheumatol. 2012 Jul-Aug; 30(4 Suppl 73):S123-5. PMID: 23078992.
      View in: PubMed
    138. Her M, Kavanaugh A. Critical analysis of economic tools and economic measurement applied to rheumatoid arthritis. Clin Exp Rheumatol. 2012 Jul-Aug; 30(4 Suppl 73):S107-11. PMID: 23078839.
      View in: PubMed
    139. Fleischmann R, Kavanaugh A, Smolen J. Methodological aspects and the interpretation of clinical trial data: lessons from the TEAR trial. Rheumatology (Oxford). 2013 Mar; 52(3):409-10. PMID: 23070312.
      View in: PubMed
    140. Wagner CL, Visvanathan S, Elashoff M, McInnes IB, Mease PJ, Krueger GG, Murphy FT, Papp K, Gomez-Reino JJ, Mack M, Beutler A, Gladman D, Kavanaugh A. Markers of inflammation and bone remodelling associated with improvement in clinical response measures in psoriatic arthritis patients treated with golimumab. Ann Rheum Dis. 2013 Jan; 72(1):83-8. PMID: 22975755; PMCID: PMC3551220.
    141. Kavanaugh A. Assessment of psoriatic nail disease activity by rheumatologists: comment on the article by Lubrano et al. Arthritis Care Res (Hoboken). 2012 Aug; 64(8):1269; author reply 1269-70. PMID: 22623218.
      View in: PubMed
    142. Kavanaugh A, van der Heijde D, McInnes IB, Mease P, Krueger GG, Gladman DD, Gómez-Reino J, Papp K, Baratelle A, Xu W, Mudivarthy S, Mack M, Rahman MU, Xu Z, Zrubek J, Beutler A. Golimumab in psoriatic arthritis: one-year clinical efficacy, radiographic, and safety results from a phase III, randomized, placebo-controlled trial. Arthritis Rheum. 2012 Aug; 64(8):2504-17. PMID: 22378566.
      View in: PubMed
    143. Kavanaugh A, Mease P. Treatment of psoriatic arthritis with tumor necrosis factor inhibitors: longer-term outcomes including enthesitis and dactylitis with golimumab treatment in the Longterm Extension of a Randomized, Placebo-controlled Study (GO-REVEAL). J Rheumatol Suppl. 2012 Jul; 89:90-3. PMID: 22751603.
      View in: PubMed
    144. Pavelka K, Kavanaugh A, Rubbert-Roth A, Ferraccioli G. Optimizing outcomes in rheumatoid arthritis patients with inadequate responses to disease-modifying anti-rheumatic drugs. Rheumatology (Oxford). 2012 Jul; 51 Suppl 5:v12-21. PMID: 22718922.
      View in: PubMed
    145. Grunke M, Witt MN, Ronneberger M, Schnez A, Laubender RP, Engelbrecht M, Kavanaugh A, Schulze-Koops H. Use of the 28-joint count yields significantly higher concordance between different examiners than the 66/68-joint count. J Rheumatol. 2012 Jul; 39(7):1334-40. PMID: 22660799.
      View in: PubMed
    146. Kavanaugh A, Martin G, Cush JJ, Bergman MJ, Fleischmann R, Troum OM, Strand V, Ruderman EM, Wells AF. Proceedings of the 2012 Rheumatology Winter Clinical Symposia. Semin Arthritis Rheum. 2012 Jun; 41(6):923-6. PMID: 22617482.
      View in: PubMed
    147. Kavanaugh A, Fleischmann RM, Emery P, Kupper H, Redden L, Guerette B, Santra S, Smolen JS. Clinical, functional and radiographic consequences of achieving stable low disease activity and remission with adalimumab plus methotrexate or methotrexate alone in early rheumatoid arthritis: 26-week results from the randomised, controlled OPTIMA study. Ann Rheum Dis. 2013 Jan; 72(1):64-71. PMID: 22562973; PMCID: PMC3551224.
    148. Singh JA, Furst DE, Bharat A, Curtis JR, Kavanaugh A, Kremer JM, Moreland LW, O'Dell J, Winthrop KL, Beukelman T, Bridges SL, Chatham WW, Paulus HE, Suarez-Almazor M, Bombardier C, Dougados M, Khanna D, King CM, Leong AL, Matteson EL, Schousboe JT, Moynihan E, Kolba KS, Jain A, Volkmann ER, Agrawal H, Bae S, Mudano AS, Patkar NM, Saag KG. 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken). 2012 May; 64(5):625-39. PMID: 22473917; PMCID: PMC4081542.
    149. Her M, Kavanaugh A. Patient-reported outcomes in rheumatoid arthritis. Curr Opin Rheumatol. 2012 May; 24(3):327-34. PMID: 22410543.
      View in: PubMed
    150. Curtis JR, Luijtens K, Kavanaugh A. Predicting future response to certolizumab pegol in rheumatoid arthritis patients: features at 12 weeks associated with low disease activity at 1 year. Arthritis Care Res (Hoboken). 2012 May; 64(5):658-67. PMID: 22231904; PMCID: PMC3330194.
    151. Strober BE, Clay Cather J, Cohen D, Crowley JJ, Gordon KB, Gottlieb AB, Kavanaugh A, Korman NJ, Krueger GG, Leonardi CL, Schwartzman S, Sobell JM, Solomon GE, Young M. A Delphi Consensus Approach to Challenging Case Scenarios in Moderate-to-Severe Psoriasis: Part 2. Dermatol Ther (Heidelb). 2012 Dec; 2(1):2. PMID: 23205325; PMCID: PMC3510406.
    152. Strober BE, Clay Cather J, Cohen D, Crowley JJ, Gordon KB, Gottlieb AB, Kavanaugh A, Korman NJ, Krueger GG, Leonardi CL, Schwartzman S, Sobell JM, Solomon GE, Young M. A Delphi Consensus Approach to Challenging Case Scenarios in Moderate-to-Severe Psoriasis: Part 1. Dermatol Ther (Heidelb). 2012 Dec; 2(1):1. PMID: 23205324; PMCID: PMC3510391.
    153. Kavanaugh A, Catalan T, Cassell S. Patient assessments of skin, joint, and nail disease activity in psoriatic arthritis. J Rheumatol. 2012 Mar; 39(3):653; author reply 654. PMID: 22383354.
      View in: PubMed
    154. Hsu S, Papp KA, Lebwohl MG, Bagel J, Blauvelt A, Duffin KC, Crowley J, Eichenfield LF, Feldman SR, Fiorentino DF, Gelfand JM, Gottlieb AB, Jacobsen C, Kalb RE, Kavanaugh A, Korman NJ, Krueger GG, Michelon MA, Morison W, Ritchlin CT, Stein Gold L, Stone SP, Strober BE, Van Voorhees AS, Weiss SC, Wanat K, Bebo BF. Consensus guidelines for the management of plaque psoriasis. Arch Dermatol. 2012 Jan; 148(1):95-102. PMID: 22250239.
      View in: PubMed
    155. Short P, Jones AC, Walker D, Kavanaugh A, Moots RJ. Working at arthritis. Rheumatology (Oxford). 2012 Feb; 51(2):201-3. PMID: 22179726.
      View in: PubMed
    156. Rosengren S, Kalunian KC, Kavanaugh A, Boyle DL. CXCL13 as a marker for outcome of rheumatoid arthritis: comment on the article by Meeuwisse et al. Arthritis Rheum. 2011 Nov; 63(11):3646-7. PMID: 21834069.
      View in: PubMed
    157. Curtis JR, Yang S, Chen L, Park GS, Bitman B, Wang B, Navarro-Millan I, Kavanaugh A. Predicting low disease activity and remission using early treatment response to antitumour necrosis factor therapy in patients with rheumatoid arthritis: exploratory analyses from the TEMPO trial. Ann Rheum Dis. 2012 Feb; 71(2):206-12. PMID: 21998118; PMCID: PMC3698970.
    158. Yazici Y, Curtis JR, Ince A, Baraf H, Malamet RL, Teng LL, Kavanaugh A. Efficacy of tocilizumab in patients with moderate to severe active rheumatoid arthritis and a previous inadequate response to disease-modifying antirheumatic drugs: the ROSE study. Ann Rheum Dis. 2012 Feb; 71(2):198-205. PMID: 21949007.
      View in: PubMed
    159. Broderick L, Tourangeau LM, Kavanaugh A, Wasserman SI. Biologic modulators in allergic and autoinflammatory diseases. Curr Opin Allergy Clin Immunol. 2011 Aug; 11(4):355-60. PMID: 21659854; PMCID: PMC3154953.
    160. Kavanaugh A, Cush JJ. Proceedings of the 2011 Rheumatology Winter Clinical Symposia--Arthur Kavanaugh, MD and John J. Cush, MD (proceedings editors) [course directors: Arthur Kavanaugh, MD, George Martin, MD]. Semin Arthritis Rheum. 2011 Apr; 40(5):479-81. PMID: 21444001.
      View in: PubMed
    161. Kavanaugh A, Mayer LF, Cush JJ, Hanauer SB. Shared experiences and best practices in the management of rheumatoid arthritis and Crohn's disease. Am J Med. 2011 Apr; 124(4 Suppl):e1-18. PMID: 21531240.
      View in: PubMed
    162. Mircic M, Kavanaugh A. Inhibition of IL6 in rheumatoid arthritis and juvenile idiopathic arthritis. Exp Cell Res. 2011 May 15; 317(9):1286-92. PMID: 21439276.
      View in: PubMed
    163. Tourangeau LM, Kavanaugh A, Wasserman SI. The role of monoclonal antibodies in the treatment of severe asthma. Ther Adv Respir Dis. 2011 Jun; 5(3):183-94. PMID: 21393345.
      View in: PubMed
    164. Khanna D, Sarkin AJ, Khanna PP, Shieh MM, Kavanaugh A, Terkeltaub RA, Lee SJ, Singh JA, Hirsch JD. Minimally important differences of the gout impact scale in a randomized controlled trial. Rheumatology (Oxford). 2011 Jul; 50(7):1331-6. PMID: 21372003; PMCID: PMC3307519.
    165. Hoff M, Kvien TK, Kälvesten J, Elden A, Kavanaugh A, Haugeberg G. Adalimumab reduces hand bone loss in rheumatoid arthritis independent of clinical response: subanalysis of the PREMIER study. BMC Musculoskelet Disord. 2011 Feb 27; 12:54. PMID: 21352592; PMCID: PMC3053306.
    166. Keystone EC, Kavanaugh A, Weinblatt ME, Patra K, Pangan AL. Clinical consequences of delayed addition of adalimumab to methotrexate therapy over 5 years in patients with rheumatoid arthritis. J Rheumatol. 2011 May; 38(5):855-62. PMID: 21285171.
      View in: PubMed
    167. Genovese MC, Kavanaugh A, Weinblatt ME, Peterfy C, DiCarlo J, White ML, O'Brien M, Grossbard EB, Magilavy DB. An oral Syk kinase inhibitor in the treatment of rheumatoid arthritis: a three-month randomized, placebo-controlled, phase II study in patients with active rheumatoid arthritis that did not respond to biologic agents. Arthritis Rheum. 2011 Feb; 63(2):337-45. PMID: 21279990.
      View in: PubMed
    168. Rosengren S, Wei N, Kalunian KC, Kavanaugh A, Boyle DL. CXCL13: a novel biomarker of B-cell return following rituximab treatment and synovitis in patients with rheumatoid arthritis. Rheumatology (Oxford). 2011 Mar; 50(3):603-10. PMID: 21098574.
      View in: PubMed
    169. Jones AC, Kavanaugh A, Walker DJ. Rheumatology and work. Rheumatology (Oxford). 2010 Nov; 49(11):2007-9. PMID: 20947529.
      View in: PubMed
    170. Cohen S, Roland P, Shoup A, Lowenstein M, Silverstein H, Kavanaugh A, Harris J. A pilot study of rituximab in immune-mediated inner ear disease. Audiol Neurootol. 2011; 16(4):214-21. PMID: 20980741.
      View in: PubMed
    171. van der Heijde D, Breedveld FC, Kavanaugh A, Keystone EC, Landewé R, Patra K, Pangan AL. Disease activity, physical function, and radiographic progression after longterm therapy with adalimumab plus methotrexate: 5-year results of PREMIER. J Rheumatol. 2010 Nov; 37(11):2237-46. PMID: 20889601.
      View in: PubMed
    172. Kavanaugh A, Menter A, Mendelsohn A, Shen YK, Lee S, Gottlieb AB. Effect of ustekinumab on physical function and health-related quality of life in patients with psoriatic arthritis: a randomized, placebo-controlled, phase II trial. Curr Med Res Opin. 2010 Oct; 26(10):2385-92. PMID: 20831455.
      View in: PubMed
    173. Weinblatt ME, Kavanaugh A, Genovese MC, Musser TK, Grossbard EB, Magilavy DB. An oral spleen tyrosine kinase (Syk) inhibitor for rheumatoid arthritis. N Engl J Med. 2010 Sep 30; 363(14):1303-12. PMID: 20879879.
      View in: PubMed
    174. Kavanaugh A. Rheumatoid arthritis: Guidelines for RA therapy-avoiding hamartia. Nat Rev Rheumatol. 2010 Sep; 6(9):505-6. PMID: 20808307.
      View in: PubMed
    175. Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO, Birnbaum NS, Burmester GR, Bykerk VP, Cohen MD, Combe B, Costenbader KH, Dougados M, Emery P, Ferraccioli G, Hazes JM, Hobbs K, Huizinga TW, Kavanaugh A, Kay J, Kvien TK, Laing T, Mease P, Ménard HA, Moreland LW, Naden RL, Pincus T, Smolen JS, Stanislawska-Biernat E, Symmons D, Tak PP, Upchurch KS, Vencovský J, Wolfe F, Hawker G. 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum. 2010 Sep; 62(9):2569-81. PMID: 20872595.
      View in: PubMed
    176. Neogi T, Aletaha D, Silman AJ, Naden RL, Felson DT, Aggarwal R, Bingham CO, Birnbaum NS, Burmester GR, Bykerk VP, Cohen MD, Combe B, Costenbader KH, Dougados M, Emery P, Ferraccioli G, Hazes JM, Hobbs K, Huizinga TW, Kavanaugh A, Kay J, Khanna D, Kvien TK, Laing T, Liao K, Mease P, Ménard HA, Moreland LW, Nair R, Pincus T, Ringold S, Smolen JS, Stanislawska-Biernat E, Symmons D, Tak PP, Upchurch KS, Vencovský J, Wolfe F, Hawker G. The 2010 American College of Rheumatology/European League Against Rheumatism classification criteria for rheumatoid arthritis: Phase 2 methodological report. Arthritis Rheum. 2010 Sep; 62(9):2582-91. PMID: 20872596; PMCID: PMC3077961.
    177. Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO, Birnbaum NS, Burmester GR, Bykerk VP, Cohen MD, Combe B, Costenbader KH, Dougados M, Emery P, Ferraccioli G, Hazes JM, Hobbs K, Huizinga TW, Kavanaugh A, Kay J, Kvien TK, Laing T, Mease P, Ménard HA, Moreland LW, Naden RL, Pincus T, Smolen JS, Stanislawska-Biernat E, Symmons D, Tak PP, Upchurch KS, Vencovsky J, Wolfe F, Hawker G. 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Ann Rheum Dis. 2010 Sep; 69(9):1580-8. PMID: 20699241.
      View in: PubMed
    178. Sarkin AJ, Levack AE, Shieh MM, Kavanaugh A, Khanna D, Singh JA, Terkeltaub RA, Lee SJ, Hirsch JD. Predictors of doctor-rated and patient-rated gout severity: gout impact scales improve assessment. J Eval Clin Pract. 2010 Dec; 16(6):1244-7. PMID: 20722884.
      View in: PubMed
    179. Kavanaugh A. Biologic agents in rheumatology: act II. Clin Exp Rheumatol. 2010 May-Jun; 28(3 Suppl 59):S2-4. PMID: 20576218.
      View in: PubMed
    180. Schoels M, Aletaha D, Funovits J, Kavanaugh A, Baker D, Smolen JS. Application of the DAREA/DAPSA score for assessment of disease activity in psoriatic arthritis. Ann Rheum Dis. 2010 Aug; 69(8):1441-7. PMID: 20525844.
      View in: PubMed
    181. Sokolove J, Strand V, Greenberg JD, Curtis JR, Kavanaugh A, Kremer JM, Anofrei A, Reed G, Calabrese L, Hooper M, Baumgartner S, Furst DE. Risk of elevated liver enzymes associated with TNF inhibitor utilisation in patients with rheumatoid arthritis. Ann Rheum Dis. 2010 Sep; 69(9):1612-7. PMID: 20448284.
      View in: PubMed
    182. Ceponis A, Kavanaugh A. Treatment of psoriatic arthritis with biological agents. Semin Cutan Med Surg. 2010 Mar; 29(1):56-62. PMID: 20430309.
      View in: PubMed
    183. Hirsch JD, Terkeltaub R, Khanna D, Singh J, Sarkin A, Shieh M, Kavanaugh A, Lee SJ. Gout disease-specific quality of life and the association with gout characteristics. Patient Relat Outcome Meas. 2010 Mar 01; 2010:1-8. PMID: 21686040.
      View in: PubMed
    184. Kavanaugh A, Keystone E, Feng J, Hooper M. Is a 12-week trial sufficient to evaluate clinical responses to etanercept or MTX treatment in early RA? Rheumatology (Oxford). 2010 Jun; 49(6):1201-3. PMID: 20181672.
      View in: PubMed
    185. Grunke M, Antoni CE, Kavanaugh A, Hildebrand V, Dechant C, Schett G, Manger B, Ronneberger M. Standardization of joint examination technique leads to a significant decrease in variability among different examiners. J Rheumatol. 2010 Apr; 37(4):860-4. PMID: 20156953.
      View in: PubMed
    186. Kavanaugh A, Lee SJ, Weng HH, Chon Y, Huang XY, Lin SL. Patient-derived joint counts are a potential alternative for determining Disease Activity Score. J Rheumatol. 2010 May; 37(5):1035-41. PMID: 20156946.
      View in: PubMed
    187. Ritchlin CT, Qureshi AA, de Vlam K, Pitzalis C, Helliwell PS, Mease PJ, Gladman DD, Krueger GG, Kavanaugh A, Fitzgerald O. Biomarkers in psoriasis and psoriatic arthritis: GRAPPA 2008. J Rheumatol. 2010 Feb; 37(2):462-7. PMID: 20147482.
      View in: PubMed
    188. Coates LC, McGonagle DM, Hodgson R, Gisondi P, Kavanaugh A, Qureshi AA, Fitzgerald O, Mease PJ, Garg A, Rosen CF, Ridley D, Gladman DD, Krueger GG, Ritchlin CT, Helliwell PS. Imaging in psoriasis and psoriatic arthritis: GRAPPA 2008. J Rheumatol. 2010 Feb; 37(2):448-52. PMID: 20147480.
      View in: PubMed
    189. Gladman DD, Landewé R, McHugh NJ, Fitzgerald O, Thaci D, Coates L, Mease PJ, Qureshi AA, Krueger GG, Ritchlin CT, Kavanaugh A, Garg A. Composite measures in psoriatic arthritis: GRAPPA 2008. J Rheumatol. 2010 Feb; 37(2):453-61. PMID: 20147481.
      View in: PubMed
    190. Lee SJ, Chinen J, Kavanaugh A. Immunomodulator therapy: monoclonal antibodies, fusion proteins, cytokines, and immunoglobulins. J Allergy Clin Immunol. 2010 Feb; 125(2 Suppl 2):S314-23. PMID: 20036416.
      View in: PubMed
    191. Kavanaugh A, Smolen JS, Emery P, Purcaru O, Keystone E, Richard L, Strand V, van Vollenhoven RF. Effect of certolizumab pegol with methotrexate on home and work place productivity and social activities in patients with active rheumatoid arthritis. Arthritis Rheum. 2009 Nov 15; 61(11):1592-600. PMID: 19877104.
      View in: PubMed
    192. Strand V, Mease P, Burmester GR, Nikaï E, Coteur G, van Vollenhoven R, Combe B, Keystone EC, Kavanaugh A. Rapid and sustained improvements in health-related quality of life, fatigue, and other patient-reported outcomes in rheumatoid arthritis patients treated with certolizumab pegol plus methotrexate over 1 year: results from the RAPID 1 randomized controlled trial. Arthritis Res Ther. 2009; 11(6):R170. PMID: 19909548; PMCID: PMC3003523.
    193. Koffeman EC, Genovese M, Amox D, Keogh E, Santana E, Matteson EL, Kavanaugh A, Molitor JA, Schiff MH, Posever JO, Bathon JM, Kivitz AJ, Samodal R, Belardi F, Dennehey C, van den Broek T, van Wijk F, Zhang X, Zieseniss P, Le T, Prakken BA, Cutter GC, Albani S. Epitope-specific immunotherapy of rheumatoid arthritis: clinical responsiveness occurs with immune deviation and relies on the expression of a cluster of molecules associated with T cell tolerance in a double-blind, placebo-controlled, pilot phase II trial. Arthritis Rheum. 2009 Nov; 60(11):3207-16. PMID: 19877047.
      View in: PubMed
    194. Chandran V, Gottlieb A, Cook RJ, Duffin KC, Garg A, Helliwell P, Kavanaugh A, Krueger GG, Langley RG, Lynde C, McHugh N, Mease P, Olivieri I, Rahman P, Rosen CF, Salvarani C, Thaci D, Toloza SM, Wong MY, Zhou QM, Gladman DD. International multicenter psoriasis and psoriatic arthritis reliability trial for the assessment of skin, joints, nails, and dactylitis. Arthritis Rheum. 2009 Sep 15; 61(9):1235-42. PMID: 19714610.
      View in: PubMed
    195. Lee SJ, Kremer J, Kavanaugh A. Treatment disparity related to race/ethnicity and education in rheumatoid arthritis patients: comment on the article by Constantinescu et al. Arthritis Rheum. 2009 Aug 15; 61(8):1141-2. PMID: 19644891.
      View in: PubMed
    196. Kavanaugh A. Therapy: Guidelines in rheumatology: quo vadis? Nat Rev Rheumatol. 2009 Aug; 5(8):423-4. PMID: 19648942.
      View in: PubMed
    197. Kavanaugh A. The efficacy of ustekinumab on the articular and dermatologic manifestations of psoriatic arthritis. Curr Rheumatol Rep. 2009 Aug; 11(4):233-4. PMID: 19691924.
      View in: PubMed
    198. Kavanaugh A. Infection prophylaxis in antirheumatic therapy: emphasis on vaccination. Curr Opin Rheumatol. 2009 Jul; 21(4):419-24. PMID: 19444117.
      View in: PubMed
    199. Strober B, Berger E, Cather J, Cohen D, Crowley JJ, Gordon KB, Gottlieb A, Horn EJ, Kavanaugh A, Korman NJ, Krueger GG, Leonardi CL, Menter A, Schwartzman S, Sobell JM, Young M. A series of critically challenging case scenarios in moderate to severe psoriasis: a Delphi consensus approach. J Am Acad Dermatol. 2009 Jul; 61(1 Suppl 1):S1-S46. PMID: 19527820.
      View in: PubMed
    200. Lee SJ, Chang H, Yazici Y, Greenberg JD, Kremer JM, Kavanaugh A. Utilization trends of tumor necrosis factor inhibitors among patients with rheumatoid arthritis in a United States observational cohort study. J Rheumatol. 2009 Aug; 36(8):1611-7. PMID: 19369454.
      View in: PubMed
    201. Kavanaugh A, McInnes I, Mease P, Krueger GG, Gladman D, Gomez-Reino J, Papp K, Zrubek J, Mudivarthy S, Mack M, Visvanathan S, Beutler A. Golimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: Twenty-four-week efficacy and safety results of a randomized, placebo-controlled study. Arthritis Rheum. 2009 Apr; 60(4):976-86. PMID: 19333944.
      View in: PubMed
    202. Khanna D, Clements PJ, Furst DE, Korn JH, Ellman M, Rothfield N, Wigley FM, Moreland LW, Silver R, Kim YH, Steen VD, Firestein GS, Kavanaugh A, Weisman M, Mayes MD, Collier D, Csuka ME, Simms R, Merkel PA, Medsger TA, Sanders ME, Maranian P, Seibold JR. Recombinant human relaxin in the treatment of systemic sclerosis with diffuse cutaneous involvement: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2009 Apr; 60(4):1102-11. PMID: 19333948; PMCID: PMC3711466.
    203. Lee SJ, Hirsch JD, Terkeltaub R, Khanna D, Singh JA, Sarkin A, Kavanaugh A. Perceptions of disease and health-related quality of life among patients with gout. Rheumatology (Oxford). 2009 May; 48(5):582-6. PMID: 19307257; PMCID: PMC2722803.
    204. Mircic M, Kavanaugh A. The clinical efficacy of tocilizumab in rheumatoid arthritis. Drugs Today (Barc). 2009 Mar; 45(3):189-97. PMID: 19436841.
      View in: PubMed
    205. Gottlieb A, Menter A, Mendelsohn A, Shen YK, Li S, Guzzo C, Fretzin S, Kunynetz R, Kavanaugh A. Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial. Lancet. 2009 Feb 21; 373(9664):633-40. PMID: 19217154.
      View in: PubMed
    206. Castro-Rueda H, Kavanaugh A. The treatment of psoriatic arthritis and inflammatory spondylitis. Curr Pain Headache Rep. 2008 Dec; 12(6):412-7. PMID: 18973733.
      View in: PubMed
    207. Weinblatt ME, Kavanaugh A, Burgos-Vargas R, Dikranian AH, Medrano-Ramirez G, Morales-Torres JL, Murphy FT, Musser TK, Straniero N, Vicente-Gonzales AV, Grossbard E. Treatment of rheumatoid arthritis with a Syk kinase inhibitor: a twelve-week, randomized, placebo-controlled trial. Arthritis Rheum. 2008 Nov; 58(11):3309-18. PMID: 18975322.
      View in: PubMed
    208. Hirsch JD, Lee SJ, Terkeltaub R, Khanna D, Singh J, Sarkin A, Harvey J, Kavanaugh A. Evaluation of an instrument assessing influence of Gout on health-related quality of life. J Rheumatol. 2008 Dec; 35(12):2406-14. PMID: 18925685.
      View in: PubMed
    209. Rosengren S, Wei N, Kalunian KC, Zvaifler NJ, Kavanaugh A, Boyle DL. Elevated autoantibody content in rheumatoid arthritis synovia with lymphoid aggregates and the effect of rituximab. Arthritis Res Ther. 2008; 10(5):R105. PMID: 18761748; PMCID: PMC2592782.
    210. Hoffman HM, Throne ML, Amar NJ, Sebai M, Kivitz AJ, Kavanaugh A, Weinstein SP, Belomestnov P, Yancopoulos GD, Stahl N, Mellis SJ. Efficacy and safety of rilonacept (interleukin-1 Trap) in patients with cryopyrin-associated periodic syndromes: results from two sequential placebo-controlled studies. Arthritis Rheum. 2008 Aug; 58(8):2443-52. PMID: 18668535.
      View in: PubMed
    211. Hennigan S, Kavanaugh A. Interleukin-6 inhibitors in the treatment of rheumatoid arthritis. Ther Clin Risk Manag. 2008 Aug; 4(4):767-75. PMID: 19209259; PMCID: PMC2621374.
    212. Hennigan S, Ackermann C, Kavanaugh A. Adalimumab in ankylosing spondylitis: an evidence-based review of its place in therapy. Core Evid. 2008 Jul 31; 2(4):295-305. PMID: 21221193; PMCID: PMC3012440.
    213. Sánchez-Guerrero J, Fragoso-Loyo HE, Neuwelt CM, Wallace DJ, Ginzler EM, Sherrer YR, McIlwain HH, Freeman PG, Aranow C, Petri MA, Deodhar AA, Blanton E, Manzi S, Kavanaugh A, Lisse JR, Ramsey-Goldman R, McKay JD, Kivitz AJ, Mease PJ, Winkler AE, Kahl LE, Lee AH, Furie RA, Strand CV, Lou L, Ahmed M, Quarles B, Schwartz KE. Effects of prasterone on bone mineral density in women with active systemic lupus erythematosus receiving chronic glucocorticoid therapy. J Rheumatol. 2008 Aug; 35(8):1567-75. PMID: 18634158.
      View in: PubMed
    214. Boehncke WH, Adebajo A, Cauli A, Nash P, Salvarani C, Kavanaugh A. Initiative for quality in psoriasis and psoriatic arthritis. J Rheumatol. 2008 Jul; 35(7):1431-3. PMID: 18609739.
      View in: PubMed
    215. Boyle DL, Kavanaugh A. The pathobiology of psoriatic synovium. Curr Opin Rheumatol. 2008 Jul; 20(4):404-7. PMID: 18525352.
      View in: PubMed
    216. Kavanaugh A, Klareskog L, van der Heijde D, Li J, Freundlich B, Hooper M. Improvements in clinical response between 12 and 24 weeks in patients with rheumatoid arthritis on etanercept therapy with or without methotrexate. Ann Rheum Dis. 2008 Oct; 67(10):1444-7. PMID: 18535115; PMCID: PMC2566536.
    217. Castro-Rueda H, Kavanaugh A. Biologic therapy for early rheumatoid arthritis: the latest evidence. Curr Opin Rheumatol. 2008 May; 20(3):314-9. PMID: 18388524.
      View in: PubMed
    218. Friedewald VE, Cather JC, Gordon KB, Kavanaugh A, Ridker PM, Roberts WC. The editor's roundtable: psoriasis, inflammation, and coronary artery disease. Am J Cardiol. 2008 Apr 15; 101(8):1119-26. PMID: 18394444.
      View in: PubMed
    219. Han C, Smolen J, Kavanaugh A, St Clair EW, Baker D, Bala M. Comparison of employability outcomes among patients with early or long-standing rheumatoid arthritis. Arthritis Rheum. 2008 Apr 15; 59(4):510-4. PMID: 18383415.
      View in: PubMed
    220. Antoni CE, Kavanaugh A, van der Heijde D, Beutler A, Keenan G, Zhou B, Kirkham B, Tutuncu Z, Burmester GR, Schneider U, Furst DE, Molitor J, Keystone E, Gladman DD, Manger B, Wassenberg S, Weier R, Wallace DJ, Weisman MH, Kalden JR, Smolen JS. Two-year efficacy and safety of infliximab treatment in patients with active psoriatic arthritis: findings of the Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT). J Rheumatol. 2008 May; 35(5):869-76. PMID: 18381786.
      View in: PubMed
    221. Ackermann C, Kavanaugh A. Economic burden of psoriatic arthritis. Pharmacoeconomics. 2008; 26(2):121-9. PMID: 18198932.
      View in: PubMed
    222. Dall'Era M, Chakravarty E, Wallace D, Genovese M, Weisman M, Kavanaugh A, Kalunian K, Dhar P, Vincent E, Pena-Rossi C, Wofsy D. Reduced B lymphocyte and immunoglobulin levels after atacicept treatment in patients with systemic lupus erythematosus: results of a multicenter, phase Ib, double-blind, placebo-controlled, dose-escalating trial. Arthritis Rheum. 2007 Dec; 56(12):4142-50. PMID: 18050206.
      View in: PubMed
    223. Kavanaugh A, Ritchlin C, Boehncke WH. Quality indicators in psoriatic arthritis. Clin Exp Rheumatol. 2007 Nov-Dec; 25(6 Suppl 47):98-101. PMID: 18021513.
      View in: PubMed
    224. Ackermann C, Kavanaugh A. Tumor necrosis factor as a therapeutic target of rheumatologic disease. Expert Opin Ther Targets. 2007 Nov; 11(11):1369-84. PMID: 18028004.
      View in: PubMed
    225. Han C, Rahman MU, Doyle MK, Bathon JM, Smolen J, Kavanaugh A, Westhovens R, St Clair EW, Baker D, Bala M. Association of anemia and physical disability among patients with rheumatoid arthritis. J Rheumatol. 2007 Nov; 34(11):2177-82. PMID: 17937474.
      View in: PubMed
    226. Kavanaugh A. Economic consequences of established rheumatoid arthritis and its treatment. Best Pract Res Clin Rheumatol. 2007 Oct; 21(5):929-42. PMID: 17870036.
      View in: PubMed
    227. Gladman DD, Inman RD, Cook RJ, Maksymowych WP, Braun J, Davis JC, Landewé RB, Mease P, Brandt J, Vargas RB, Chandran V, Helliwell P, Kavanaugh A, O'Shea FD, Khan MA, Pipitone N, Rahman P, Reveille JD, Stone MA, Taylor W, Veale DJ, van der Heijde D. International spondyloarthritis interobserver reliability exercise--the INSPIRE study: II. Assessment of peripheral joints, enthesitis, and dactylitis. J Rheumatol. 2007 Aug; 34(8):1740-5. PMID: 17659754.
      View in: PubMed
    228. Lee SJ, Kavanaugh A, Lenert L. Electronic and computer-generated patient questionnaires in standard care. Best Pract Res Clin Rheumatol. 2007 Aug; 21(4):637-47. PMID: 17678825.
      View in: PubMed
    229. Kavanaugh A, Rosengren S, Lee SJ, Hammaker D, Firestein GS, Kalunian K, Wei N, Boyle DL. Assessment of rituximab's immunomodulatory synovial effects (ARISE trial). 1: clinical and synovial biomarker results. Ann Rheum Dis. 2008 Mar; 67(3):402-8. PMID: 17644541; PMCID: PMC2754142.
    230. Kavanaugh A. A conversation with Arthur Kavanaugh. Manag Care Interface. 2007 Jul; 20(7):26-7, 30. PMID: 17849730.
      View in: PubMed
    231. Gladman DD, Inman RD, Cook RJ, van der Heijde D, Landewé RB, Braun J, Davis JC, Mease P, Brandt J, Vargas RB, Chandran V, Helliwell P, Kavanaugh A, O'Shea FD, Khan MA, Pipitone N, Rahman P, Reveille JD, Stone MA, Taylor W, Veale DJ, Maksymowych WP. International spondyloarthritis interobserver reliability exercise--the INSPIRE study: I. Assessment of spinal measures. J Rheumatol. 2007 Aug; 34(8):1733-9. PMID: 17611985.
      View in: PubMed
    232. Kavanaugh A. Economic issues with new rheumatologic therapeutics. Curr Opin Rheumatol. 2007 May; 19(3):272-6. PMID: 17414954.
      View in: PubMed
    233. Gladman DD, Mease PJ, Healy P, Helliwell PS, Fitzgerald O, Cauli A, Lubrano E, Krueger GG, van der Heijde D, Veale DJ, Kavanaugh A, Nash P, Ritchlin C, Taylor W, Strand V. Outcome measures in psoriatic arthritis. J Rheumatol. 2007 May; 34(5):1159-66. PMID: 17477479.
      View in: PubMed
    234. Kavanaugh A. Current treatments for rheumatoid arthritis. Am J Orthop (Belle Mead NJ). 2007 Mar; 36(3 Suppl):4-7. PMID: 17491580.
      View in: PubMed
    235. Tutuncu Z, Kavanaugh A. Rheumatic disease in the elderly: rheumatoid arthritis. Rheum Dis Clin North Am. 2007 Feb; 33(1):57-70. PMID: 17367692.
      View in: PubMed
    236. Han C, Smolen JS, Kavanaugh A, van der Heijde D, Braun J, Westhovens R, Zhao N, Rahman MU, Baker D, Bala M. The impact of infliximab treatment on quality of life in patients with inflammatory rheumatic diseases. Arthritis Res Ther. 2007; 9(5):R103. PMID: 17922913; PMCID: PMC2212571.
    237. Kavanaugh A. Interleukin-6 inhibition and clinical efficacy in rheumatoid arthritis treatment--data from randomized clinical trials. Bull NYU Hosp Jt Dis. 2007; 65 Suppl 1:S16-20. PMID: 17708740.
      View in: PubMed
    238. Cassell SE, Bieber JD, Rich P, Tutuncu ZN, Lee SJ, Kalunian KC, Wu CW, Kavanaugh A. The modified Nail Psoriasis Severity Index: validation of an instrument to assess psoriatic nail involvement in patients with psoriatic arthritis. J Rheumatol. 2007 Jan; 34(1):123-9. PMID: 17216680.
      View in: PubMed
    239. Lee SJ, Kavanaugh A. Biologic agents in rheumatology: safety considerations. Rheum Dis Clin North Am. 2006 Dec; 32 Suppl 1:3-10. PMID: 17410696.
      View in: PubMed
    240. Kavanaugh A, Krueger GG, Beutler A, Guzzo C, Zhou B, Dooley LT, Mease PJ, Gladman DD, de Vlam K, Geusens PP, Birbara C, Halter DG, Antoni C. Infliximab maintains a high degree of clinical response in patients with active psoriatic arthritis through 1 year of treatment: results from the IMPACT 2 trial. Ann Rheum Dis. 2007 Apr; 66(4):498-505. PMID: 17114188; PMCID: PMC1856065.
    241. Kavanaugh A, Fransen J. Defining remission in psoriatic arthritis. Clin Exp Rheumatol. 2006 Nov-Dec; 24(6 Suppl 43):S-83-7. PMID: 17083768.
      View in: PubMed
    242. Hata T, Kavanaugh A. Rheumatoid arthritis in dermatology. Clin Dermatol. 2006 Sep-Oct; 24(5):430-7. PMID: 16966022.
      View in: PubMed
    243. Kavanaugh A, Antoni C, Mease P, Gladman D, Yan S, Bala M, Zhou B, Dooley LT, Beutler A, Guzzo C, Krueger GG. Effect of infliximab therapy on employment, time lost from work, and productivity in patients with psoriatic arthritis. J Rheumatol. 2006 Nov; 33(11):2254-9. PMID: 16960923.
      View in: PubMed
    244. Kavanaugh A. Is there a pharmacoeconomic argument supporting the use of tumor necrosis factor inhibitors in early rheumatoid arthritis? Nat Clin Pract Rheumatol. 2006 Jul; 2(7):346-7. PMID: 16932716.
      View in: PubMed
    245. Kavanaugh A, Tutuncu Z, Catalan-Sanchez T. Update on anti-tumor necrosis factor therapy in the spondyloarthropathies including psoriatic arthritis. Curr Opin Rheumatol. 2006 Jul; 18(4):347-53. PMID: 16763453.
      View in: PubMed
    246. Kavanaugh A. Implications of radiographic joint damage in rheumatoid arthritis: comment on the editorial by Weisman. Arthritis Rheum. 2006 Jun; 54(6):2035. PMID: 16732575.
      View in: PubMed
    247. Cassell S, Kavanaugh A. Therapies for psoriatic nail disease. A systematic review. J Rheumatol. 2006 Jul; 33(7):1452-6. PMID: 16724366.
      View in: PubMed
    248. Kavanaugh A, Ritchlin CT. Systematic review of treatments for psoriatic arthritis: an evidence based approach and basis for treatment guidelines. J Rheumatol. 2006 Jul; 33(7):1417-21. PMID: 16724373.
      View in: PubMed
    249. Kavanaugh A. B cell targeted therapies: safety considerations. J Rheumatol Suppl. 2006 May; 77:18-23. PMID: 16652441.
      View in: PubMed
    250. Emery P, Fleischmann R, Filipowicz-Sosnowska A, Schechtman J, Szczepanski L, Kavanaugh A, Racewicz AJ, van Vollenhoven RF, Li NF, Agarwal S, Hessey EW, Shaw TM. The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial. Arthritis Rheum. 2006 May; 54(5):1390-400. PMID: 16649186.
      View in: PubMed
    251. Kavanaugh A. Anakinra (interleukin-1 receptor antagonist) has positive effects on function and quality of life in patients with rheumatoid arthritis. Adv Ther. 2006 Mar-Apr; 23(2):208-17. PMID: 16751154.
      View in: PubMed
    252. Wagelie-Steffen AL, Kavanaugh A, Wasserman SI. Biologic therapies for the treatment of asthma. Clin Chest Med. 2006 Mar; 27(1):133-47, vii. PMID: 16543058.
      View in: PubMed
    253. Lee SJ, Terkeltaub RA, Kavanaugh A. Recent developments in diet and gout. Curr Opin Rheumatol. 2006 Mar; 18(2):193-8. PMID: 16462528.
      View in: PubMed
    254. Kavanaugh A. The pharmacoeconomics of newer therapeutics for rheumatic diseases. Rheum Dis Clin North Am. 2006 Feb; 32(1):45-56, viii. PMID: 16504820.
      View in: PubMed
    255. Lee SJ, Kavanaugh A. 4. Autoimmunity, vasculitis, and autoantibodies. J Allergy Clin Immunol. 2006 Feb; 117(2 Suppl Mini-Primer):S445-50. PMID: 16455344.
      View in: PubMed
    256. Kavanaugh A, Antoni CE, Gladman D, Wassenberg S, Zhou B, Beutler A, Keenan G, Burmester G, Furst DE, Weisman MH, Kalden JR, Smolen J, van der Heijde D. The Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT): results of radiographic analyses after 1 year. Ann Rheum Dis. 2006 Aug; 65(8):1038-43. PMID: 16439444; PMCID: PMC1798249.
    257. Breedveld FC, Weisman MH, Kavanaugh A, Cohen SB, Pavelka K, van Vollenhoven R, Sharp J, Perez JL, Spencer-Green GT. The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum. 2006 Jan; 54(1):26-37. PMID: 16385520.
      View in: PubMed
    258. Lee SJ, Lenert L, Weisman S, Kavanaugh A. Factors affecting rheumatoid arthritis patients' decisions to participate in clinical trials. J Rheumatol. 2005 Dec; 32(12):2317-25. PMID: 16331756.
      View in: PubMed
    259. Kavanaugh A. Macromolecule tumor necrosis factor inhibitors: are more better? J Rheumatol. 2005 Dec; 32(12):2285-7. PMID: 16331750.
      View in: PubMed
    260. Pincus T, Yazici Y, Yazici H, Kavanaugh A, Kremer JM, Wolfe F. Radiographic benefit without clinical improvement in infliximab-treated patients with rheumatoid arthritis: comment on the article by Smolen et al. Arthritis Rheum. 2005 Dec; 52(12):4044-5; author reply 4045-7. PMID: 16320353.
      View in: PubMed
    261. Genovese MC, Chakravarty EF, Boyle DL, Tutuncu Z, Thorburn CM, Halilhodzic M, Kroll S, Baughman J, Stewart S, Kavanaugh A. A randomized, blinded, parallel group, placebo controlled pilot study evaluating the effect of PVAC treatment in patients with diffuse systemic sclerosis. J Rheumatol. 2005 Dec; 32(12):2345-50. PMID: 16331761.
      View in: PubMed
    262. Gladman DD, Mease PJ, Krueger G, van der Heidje DM, Antoni C, Helliwell PS, Kavanaugh A, Nash P, Ritchlin CT, Strand CV, Taylor W. Outcome measures in psoriatic arthritis. J Rheumatol. 2005 Nov; 32(11):2262-9. PMID: 16265714.
      View in: PubMed
    263. Kavanaugh A. Health economics: implications for novel antirheumatic therapies. Ann Rheum Dis. 2005 Nov; 64 Suppl 4:iv65-9. PMID: 16239392; PMCID: PMC1766909.
    264. Lee SJ, Kavanaugh A. Adverse reactions to biologic agents: focus on autoimmune disease therapies. J Allergy Clin Immunol. 2005 Oct; 116(4):900-5. PMID: 16210067.
      View in: PubMed
    265. Chang J, Kavanaugh A. Novel therapies for rheumatoid arthritis. Pathophysiology. 2005 Oct; 12(3):217-25. PMID: 16099629.
      View in: PubMed
    266. Cassell S, Kavanaugh A. Psoriatic arthritis: pathogenesis and novel immunomodulatory approaches to treatment. J Immune Based Ther Vaccines. 2005 Sep 02; 3:6. PMID: 16138929; PMCID: PMC1208938.
    267. Tutuncu Z, Kavanaugh A, Zvaifler N, Corr M, Deutsch R, Boyle D. Fcgamma receptor type IIIA polymorphisms influence treatment outcomes in patients with inflammatory arthritis treated with tumor necrosis factor alpha-blocking agents. Arthritis Rheum. 2005 Sep; 52(9):2693-6. PMID: 16142749.
      View in: PubMed
    268. Kavanaugh A, Cassell S. The assessment of disease activity and outcomes in psoriatic arthritis. Clin Exp Rheumatol. 2005 Sep-Oct; 23(5 Suppl 39):S142-7. PMID: 16273798.
      View in: PubMed
    269. Kavanaugh A, Antoni C, Krueger GG, Yan S, Bala M, Dooley LT, Beutler A, Guzzo C, Gladman D. Infliximab improves health related quality of life and physical function in patients with psoriatic arthritis. Ann Rheum Dis. 2006 Apr; 65(4):471-7. PMID: 16096330; PMCID: PMC1798094.
    270. Tutuncu Z, Kavanaugh A. Rheumatic disease in the elderly: rheumatoid arthritis. Clin Geriatr Med. 2005 Aug; 21(3):513-25, vi. PMID: 15911204.
      View in: PubMed
    271. Kavanaugh A, Cassell S. Outcome measures in psoriatic arthritis. Curr Rheumatol Rep. 2005 Jun; 7(3):195-200. PMID: 15918995.
      View in: PubMed
    272. Antoni CE, Kavanaugh A, Kirkham B, Tutuncu Z, Burmester GR, Schneider U, Furst DE, Molitor J, Keystone E, Gladman D, Manger B, Wassenberg S, Weier R, Wallace DJ, Weisman MH, Kalden JR, Smolen J. Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT). Arthritis Rheum. 2005 Apr; 52(4):1227-36. PMID: 15818699.
      View in: PubMed
    273. Kavanaugh A. Ethical and practical issues in conducting clinical trials in psoriasis and psoriatic arthritis. Ann Rheum Dis. 2005 Mar; 64 Suppl 2:ii46-8. PMID: 15708936; PMCID: PMC1766869.
    274. Keystone EC, Kavanaugh A. What to do with TNF failures. Expert Opin Drug Saf. 2005 Mar; 4(2):149-55. PMID: 15794709.
      View in: PubMed
    275. Kavanaugh A, Cohen S, Cush JJ. The evolving use of tumor necrosis factor inhibitors in rheumatoid arthritis. J Rheumatol. 2004 Oct; 31(10):1881-4. PMID: 15468347.
      View in: PubMed
    276. Petri MA, Mease PJ, Merrill JT, Lahita RG, Iannini MJ, Yocum DE, Ginzler EM, Katz RS, Gluck OS, Genovese MC, Van Vollenhoven R, Kalunian KC, Manzi S, Greenwald MW, Buyon JP, Olsen NJ, Schiff MH, Kavanaugh A, Caldwell JR, Ramsey-Goldman R, St Clair EW, Goldman AL, Egan RM, Polisson RP, Moder KG, Rothfield NF, Spencer RT, Hobbs K, Fessler BJ, Calabrese LH, Moreland LW, Cohen SB, Quarles BJ, Strand V, Gurwith M, Schwartz KE. Effects of prasterone on disease activity and symptoms in women with active systemic lupus erythematosus. Arthritis Rheum. 2004 Sep; 50(9):2858-68. PMID: 15452837.
      View in: PubMed
    277. Kremer J, Genovese M, Cannon GW, Caldwell J, Cush J, Furst DE, Luggen M, Keystone E, Bathon J, Kavanaugh A, Ruderman E, Coleman P, Curtis D, Kopp E, Kantor S, Weisman M, Waltuck J, Lindsley HB, Markenson J, Crawford B, Fernando I, Simpson K, Strand V. Combination leflunomide and methotrexate (MTX) therapy for patients with active rheumatoid arthritis failing MTX monotherapy: open-label extension of a randomized, double-blind, placebo controlled trial. J Rheumatol. 2004 Aug; 31(8):1521-31. PMID: 15290730.
      View in: PubMed
    278. Kavanaugh A, Han C, Bala M. Functional status and radiographic joint damage are associated with health economic outcomes in patients with rheumatoid arthritis. J Rheumatol. 2004 May; 31(5):849-55. PMID: 15124242.
      View in: PubMed
    279. Bieber J, Kavanaugh A. Consideration of the risk and treatment of tuberculosis in patients who have rheumatoid arthritis and receive biologic treatments. Rheum Dis Clin North Am. 2004 May; 30(2):257-70, v. PMID: 15172039.
      View in: PubMed
    280. Keystone EC, Kavanaugh A, Sharp JT, Tannenbaum H, Hua Y, Teoh LS, Fischkoff SA, Chartash EK. Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial. Arthritis Rheum. 2004 May; 50(5):1400-11. PMID: 15146409.
      View in: PubMed
    281. Wiik AS, Gordon TP, Kavanaugh A, Lahita RG, Reeves W, van Venrooij WJ, Wilson MR, Fritzler M. Cutting edge diagnostics in rheumatology: the role of patients, clinicians, and laboratory scientists in optimizing the use of autoimmune serology. Arthritis Rheum. 2004 Apr 15; 51(2):291-8. PMID: 15077275.
      View in: PubMed
    282. Athale N, Sturley A, Skoczen S, Kavanaugh A, Lenert L. A web-compatible instrument for measuring self-reported disease activity in arthritis. J Rheumatol. 2004 Feb; 31(2):223-8. PMID: 14760788.
      View in: PubMed
    283. Shah M, Adams-Huet B, Kavanaugh A, Coyle Y, Lipsky P. Nutrient intake and diet quality in patients with systemic lupus erythematosus on a culturally sensitive cholesterol lowering dietary program. J Rheumatol. 2004 Jan; 31(1):71-5. PMID: 14705221.
      View in: PubMed
    284. Boyle DL, Rosengren S, Bugbee W, Kavanaugh A, Firestein GS. Quantitative biomarker analysis of synovial gene expression by real-time PCR. Arthritis Res Ther. 2003; 5(6):R352-60. PMID: 14680510; PMCID: PMC333415.
    285. Lee SJ, Kavanaugh A. Pharmacological treatment of established rheumatoid arthritis. Best Pract Res Clin Rheumatol. 2003 Oct; 17(5):811-29. PMID: 12915159.
      View in: PubMed
    286. Lee SJ, Yedla P, Kavanaugh A. Secondary immune deficiencies associated with biological therapeutics. Curr Allergy Asthma Rep. 2003 Sep; 3(5):389-95. PMID: 12906774.
      View in: PubMed
    287. Weisman MH, Gano AD, Gabriel SE, Hochberg MC, Kavanaugh A, Ofman JJ, Prashker M, Suarez-Almazor ME, Yelin E, Nakelsky SD, Croft JD. Reading and interpreting economic evaluations in rheumatoid arthritis: an assessment of selected instruments for critical appraisal. J Rheumatol. 2003 Aug; 30(8):1739-47. PMID: 12913929.
      View in: PubMed
    288. Kavanaugh A, Genovese M, Baughman J, Kivitz A, Bulpitt K, Olsen N, Weisman M, Matteson E, Furst D, van Vollenhoven R, Anderson J, Cohen S, Wei N, Meijerink J, Jacobs C, Mocci S. Allele and antigen-specific treatment of rheumatoid arthritis: a double blind, placebo controlled phase 1 trial. J Rheumatol. 2003 Mar; 30(3):449-54. PMID: 12610799.
      View in: PubMed
    289. Kavanaugh A, Solomon DH. Guidelines for immunologic laboratory testing in the rheumatic diseases: anti-DNA antibody tests. Arthritis Rheum. 2002 Oct 15; 47(5):546-55. PMID: 12382306.
      View in: PubMed
    290. Wong JB, Singh G, Kavanaugh A. Estimating the cost-effectiveness of 54 weeks of infliximab for rheumatoid arthritis. Am J Med. 2002 Oct 01; 113(5):400-8. PMID: 12401535.
      View in: PubMed
    291. Shah M, Kavanaugh A, Coyle Y, Adams-Huet B, Lipsky PE. Effect of a culturally sensitive cholesterol lowering diet program on lipid and lipoproteins, body weight, nutrient intakes, and quality of life in patients with systemic lupus erythematosus. J Rheumatol. 2002 Oct; 29(10):2122-8. PMID: 12375321.
      View in: PubMed
    292. St Clair EW, Wagner CL, Fasanmade AA, Wang B, Schaible T, Kavanaugh A, Keystone EC. The relationship of serum infliximab concentrations to clinical improvement in rheumatoid arthritis: results from ATTRACT, a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2002 Jun; 46(6):1451-9. PMID: 12115174.
      View in: PubMed
    293. Kavanaugh A. Combination cytokine therapy: the next generation of rheumatoid arthritis therapy? Arthritis Rheum. 2002 Feb; 47(1):87-92. PMID: 11932883.
      View in: PubMed
    294. Kavanaugh A, Lipsky P. Biologics in the treatment of rheumatoid arthritis: mechanisms of action. Curr Dir Autoimmun. 2001; 3:240-73. PMID: 11791469.
      View in: PubMed